Compositions comprising a sunscreen active agent

Abstract

The present invention relates to a composition comprising at least one sunscreen active agent, at least one cooling compound and / or at least one cooling enhancing compound.

Description

[0001] COMPOSITIONS COMPRISING A SUNSCREEN ACTIVE AGENT

[0002] Technical Field

[0003] The present invention relates to a composition comprising at least one sunscreen active agent, at least one cooling compound and / or at least one cooling enhancing compound.

[0004] Background of the Invention

[0005] The use of compositions containing sunscreen active agents (also called sunscreens) is very common nowadays. The sunscreen active agents in such compositions protect keratinous material such as in particular the skin from the harm caused by UV radiation, including harm from both UVA and UVB rays, which are known to not only contribute to skin wrinkling but also to foster the development of skin diseases, such as lupus erythematosus and melanoma and non-melanoma skin cancer. Thus, to get ultimate skin protection, there's a constantly increasing need for sunscreens exhibiting high SPF’s (Sun Protection Factor).

[0006] In addition to this protection requirement, the consumer demand for new sensory experience is more and more important and is driving the development of new compositions.

[0007] Moreover, sunscreen formulations are often greasy and provide a gloss on the skin which is unwanted by the consumer. Usually, this glossy effect is reduced by incorporating additional ingredients in the sunscreen formulation.

[0008] There is therefore still a need to provide new sunscreen compositions providing new sensory experience for consumers (such as cooling effect and olfactive experience), while not compromising on the protection requirement of said sunscreen compositions. Moreover, there is also a need to provide new sunscreen compositions having a reduced glossy effect on the skin. The present invention is proposing a solution to the above-mentioned problem by providing new compositions.

[0009] Detailed description of the invention

[0010] The present invention relates to a composition comprising:

[0011] - at least one sunscreen active agent,

[0012] - at least one cooling compound and / or at least one cooling enhancing compound, and

[0013] - optionally at least one hydrophobic material, preferably a perfume oil.

[0014] Sunscreen active agent

[0015] The term ‘sunscreen active agent’ as used herein refers to compounds absorbing light in the IIV-B and / or the UVA-range (also referred to LIVA-, UVB- and broadband (UVA&B) filters). Preferably, such compounds have an E1 / 1 value (i.e. UV absorbance at a concentration of 1 % at 1 cm thickness of absorbing layer at Xmax) of at least 150, more preferably of at least 170, most preferably of at least 180.

[0016] Preferred UVA filters generally absorb radiation in the 320 to 400 nm region of the ultraviolet spectrum. Examples of preferred UVA absorbers include dibenzoyl methanes or dialkylamino hydroxybenzoyl alkyl benzoate.

[0017] Preferred UVB filters absorb radiation in the 280 to 320 nm region of the ultraviolet spectrum. Examples of preferred UVB absorbers include cinnamates, diphenylacrylates, benzalmalonates, triazines and salicylates.

[0018] Preferred broadband UV filters provide substantial broad-spectrum protection from both UVA and UVB rays. Examples of preferred broadband absorbers include mincronized organic UV-filters such as methylene bis-benzotriazolyl tetramethylbutylphenol. The sunscreen active agent(s) present in the compositions of the present invention can be organic sunscreen active agents (organic UV-filters) and / or inorganic sunscreen active agents (inorganic UV-filters) such as for example, physical blockers such as titanium dioxide or zinc oxide. Further, the sunscreen active agent(s) present in the compositions of the present invention can be soluble in water, soluble in nonaqueous material, and / or insoluble. Preferred sunscreen active agents according to the present invention are the organic sunscreen active agents.

[0019] Preferably, in all embodiments of the present invention combinations of two or more, preferably of three or more, even more preferably of four and more different UV-filters are used, such as combinations from 2 to 10, from 3 to 9 or from 4 to 7 different UV-filters. Advantageously, the two or more, preferably the two more, preferably three or more, even more preferably the four and more different UV-filters are selected from the group of organic UV-filters with all the preferences and definitions as given herein.

[0020] Preferably, in all embodiments of the present invention the total amount of all sunscreen active agent(s) in the compositions according to the invention is selected in the range from about 1 to about 50 wt.-% with respect to the total weight of the composition, preferably from about 3 to about 40wt.-% with respect to the total weight of the composition, more preferably from about 5 to about 30 wt.-%, from about 10 to 25 wt.-% or from about 15 to 25 wt.-%, with respect to the total weight of the composition, including all ranges and subranges therebetween.

[0021] It is also preferred in all embodiments of the present invention, that the amount of all UV filters present in the composition according to the present invention is selected such that the SPF of the final composition (in vivo SPF according to ISO 24333) is at least 10, preferably at least 15, more preferably at least 20.

[0022] Organic UV-filters particular useful herein include anthranilates; cinnamic derivatives; dibenzoylmethane derivatives; salicylic derivatives; camphor derivatives; triazine derivatives, such as those disclosed in Patent Applications U.S. Pat. No. 4,367,390, EP 863 145, EP 517 104, EP 570 838, EP 796 851 , EP 775698, EP 878 469, EP 933 376, EP 507 691 , EP 507 692, EP 790 243 and EP 944 624; benzophenone derivatives; |3,|3-diphenylacrylate derivatives; benzotriazole derivatives; benzalmalonate derivatives; benzimidazole derivatives; imidazolines; bisbenzoazolyl derivatives as disclosed in Patents EP 669 323 and U.S. Pat. No. 2,463,264; p- aminobenzoic acid (PABA) derivatives; methylenebis(hydroxyphenylbenzotriazole) derivatives as disclosed in Applications U.S. Pat. Nos. 5,237,071 and 5, 166,355, GB 2 303 549, DE 197 26 184 and EP 893 1 19; screening polymers and screening silicones, such as those disclosed in particular in Application WO 93 / 04665; dimers derived from a-alkylstyrene, such as those disclosed in Patent Application DE 198 55 649; 4,4-diarylbutadienes as disclosed in Applications EP 0 967 200, DE 197 46 654, DE 197 55 649, EP-A-1 008 586, EP 1 133 980 and EP 133 981 ; and their mixtures.

[0023] By way of illustration, mention may be made, as sunscreen active agents which are generally active in the UV-A and / or UV-B regions, denoted below under their INCI names, of: p-aminobenzoic acid (PABA) derivatives, in particular PABA, ethyl PABA, ethyl dihydroxypropyl PABA, ethylhexyl dimethyl PABA, glyceryl PABA or PEG-25 PABA, salicylic derivatives, in particular homosalate (HMS), ethylhexyl salicylate (EHS), dipropylene glycol salicylate, or TEA salicylate; dibenzoylmethane derivatives, in particular butyl methoxydibenzoylmethane (BMDBM), or isopropyl dibenzoylmethane; cinnamic derivatives, in particular ethylhexyl methoxycinnamate (QMS), isopropyl methoxycinnamate, isoamyl methoxycinnamate, cinoxate, DEA methoxycinnamate, diisopropyl methyl cinnamate, or glyceryl ethylhexanoate dimethoxycinnamate, |3,|3-diphenylacrylate derivatives, in particular octocrylene (OC) or etocrylene, benzophenone, in particular benzophenone-1 , benzophenone-2, benzophenone-3 or oxybenzone, benzophenone-4, benzophenone-5, benzophenone-6, benzophenone-8, benzophenone-9, benzophenone-12, or n-hexyl 2-(4-diethylamino-2- hydroxybenzoyl)benzoate (DHHB), benzylidene camphor derivatives, in particular 3-benzylidene camphor, 4-methylbenzylidene camphor, benzylidene camphor sulphonic acid, camphor benzalkonium methosulphate, terephthalylidene dicamphor sulphonic acid, or polyacrylamidomethyl benzylidene, benzimidazole derivatives, in particular phenylbenzimidazole sulphonic acid (HS), or disodium phenyl dibenzimidazole tetrasulphonate, triazine derivatives, in particular bis-ethylhexyloxyphenol methoxyphenyl triazine (BEMT), ethylhexyl triazone (EHT), diethylhexyl butamido triazone (DBT), or 2,4,6-tris(diisobutyl 4'-amino- benzalmalonate)-s-triazine, benzotriazole derivatives, in particular drometrizole trisiloxane or insoluble organic sunscreen active agents such as methylene bisbenzotriazolyl tetramethylbutylphenol (MBBT) and tris-biphenyl triazine (A2B), which are generally sold in the form of aqueous dispersions of the active UV filter e.g. under the tradename PARSOL® MAX (MBBT) from DSM Nutritional Products or Tinosorb® A2B (A2B) from BASF, anthranilic derivatives in particular menthyl anthranilate, imidazoline derivatives, in particular ethylhexyl dimethoxybenzylidene dioxoimidazoline propionate, benzalmalonate derivatives, in particular polyorganosiloxane comprising benzalmalonate functional groups (e.g. commercially available under the INCI name: polysilicone-15), 4,4-diarylbutadiene derivatives, in particular 1 ,1 '-dicarboxy (2,2'-dimethylpropyl)-4,4- diphenylbutadiene, and their mixtures.

[0024] Particular preferred organic sunscreen active agents (organic UV-filters) according to the present invention include homosalate (e.g. sold under the trade name "PARSOL® HMS"), ethylhexyl salicylate (e.g. sold under the trade name "PARSOL® EHS"), polysilicone-15 (sold in particular under the trade name "PARSOL® SLX"), ethylhexyl methoxycinnamate (e.g. sold under the trade name "PARSOL® MCX"), octocrylene (e.g. sold under the trade name "PARSOL® 340"), phenylbenzimidazole sulphonic acid (e.g. sold under the trade name "PARSOL® HS") or a salt thereof, e.g. being formed during the preparation of the composition with a neutralization agent such as triethanolamine of sodium hydroxide, bis-ethylhexyloxyphenol methoxyphenyl triazine (e.g. sold under the trade name "PARSOL® SHIELD"), ethylhexyl triazone (e.g. sold under the trade name "PARSOL® EHT"), diethylhexyl butamido triazone (e.g. commercially available under the trade name Uvasaorb HEB), methylene bisbenzotriazolyl tetramethylbutylphenol (e.g. sold under the trade name "PARSOL® MAX"), tris-biphenyl triazine (e.g. sold under the trade name Uvinul A2B), butyl methoxydibenzoylmethane (sold in particular under the trade name "Parsol 1789"), diethylamino hydroxybenzoyl hexyl benzoate (e.g. sold under the trade name Uvinul A Plus), and their mixtures.

[0025] Most preferred organic sunscreen active agents (organic UV-filters) to be used in all embodiments of the present invention are selected from the group consisting of ethylhexyl salicylate, polysilicone-15, ethylhexyl methoxycinnamate, octocrylene, phenylbenzimidazole sulphonic acid or a salt thereof, bis-ethylhexyloxyphenol methoxyphenyl triazine, ethylhexyl triazone, diethylhexyl butamido triazone, methylene bisbenzotriazolyl tetramethylbutylphenol, butyl methoxydibenzoylmethane, diethylamino hydroxybenzoyl hexyl benzoate as well as any mixtures thereof.

[0026] Preferably, in all embodiments of the present invention, the (total) amount of the organic UV-filters in the compositions according to the present invention is selected in the range from 0.5 to 30 wt.-%, more preferably in the range from 1 to 25 wt.-%, and most preferably in the range from 1 to 25 wt.-%, such as from 1 to 15 wt.-%, based on the total weight of the composition. Further suitable amounts are selected in the range from 5 to 30 wt.-%, 10 to 30 wt.-%, 15 to 30 wt.-%, from 5 to 25 wt.-%, 10 to 25 wt.-% or from 15 to 25 wt.-%, based on the total weight of the composition.

[0027] In all embodiments of the present invention, the amount of ethylhexyl salicylate in the compositions according to the present invention is advantageously selected in the range from 0.5 to 5 wt.-%., preferably in the range from 0.5 to 4 wt.-%, 0.5 to 3 wt.-%, 0.5 to 2 wt.-%, 0.5 to 1 wt.-%, such as for instance in the range from 1 to 5 wt.-%, from 2 to 5 wt.-%, from 3 to 5 wt.-% or from 4 to 5 wt.-%, based on the total weight of the composition.

[0028] In all embodiments of the present invention, the amount of polysilicone-15 in the compositions according to the present invention is advantageously selected in the range from 0.4 to 10 wt.-%., preferably in the range from 0.4 to 9 wt.-%, 0.4 to 8 wt.-%, 0.4 to 7 wt.-%, 0.4 to 6 wt.-%, 0.4 to 5 wt.-%, 0.4 to 4 wt.-%, 0.4 to 3 wt.-%, 0.5 to 3 wt.-%, 0.8 to 9 wt.-%, 0.8 to 8 wt.-%, 0.8 to 7 wt.-%, 0.8 to 6 wt.-%, 0.8 to 5 wt.-%, 0.8 to 4 wt.-%, 0.8 to 3 wt.-%, such as for instance in the range from 1 to 5 wt.-%, from 1 to 3 wt.-%, from 1 to 2.5 wt.-% or from 1 .5 to 2.5 wt.-%, based on the total weight of the composition.

[0029] In all embodiments of the present invention, the amount of ethylhexyl methoxycinnamate in the compositions according to the present invention is advantageously selected in the range from 0.5 to 10 wt.-%., preferably in the range from 0.5 to 9 wt.-%, 0.5 to 8 wt.-%, 0.5 to 7 wt.-%, 0.5 to 6 wt.-%, 0.5 to 5 wt.-%, such as for instance in the range from 1 to 10 wt.-%, from 2 to 10 wt.-%, from 3 to 10 wt.-% or from 2 to 7.5 wt.-%, based on the total weight of the composition. In all embodiments of the present invention, the amount of octocrylene in the compositions according to the present invention is advantageously selected in the range from 0.5 to 10 wt.-%., preferably in the range from 0.5 to 8 wt.-%, 1 to 10 wt.-%,

[0030] 2 to 10 wt.-%, 3 to 10 wt.-%, such as for instance in the range from 5 to 10 wt.-%, from 6 to 10 wt.-% or from 7 to 10 wt.-%, based on the total weight of the composition.

[0031] In all embodiments of the present invention, the amount of phenylbenzimidazole sulphonic acid or a salt thereof in the compositions according to the present invention is advantageously selected in the range from 0.5 to 5 wt.-%., preferably in the range from 0.5 to 4 wt.-%, 0.5 to 3 wt.-%, 1 to 2.5 wt.-%, 1 to 3 wt.-% or 1 to 4 wt.-%, based on the total weight of the composition.

[0032] In all embodiments of the present invention, the amount of bis-ethylhexyloxyphenol methoxyphenyl triazine in the compositions according to the present invention is advantageously selected in the range from 0.4 to 10 wt.-%., preferably in the range from 0.4 to 9 wt.-%, 0.4 to 8 wt.-%, 0.4 to 7 wt.-%, 0.4 to 6 wt.-%, 0.4 to 5 wt.-%, 0.4 to 4 wt.-%, 0.4 to 3 wt.-%, 0.5 to 3 wt.-%, 0.8 to 9 wt.-%, 0.8 to 8 wt.-%, 0.8 to 7 wt.- %, 0.8 to 6 wt.-%, 0.8 to 5 wt.-%, 0.8 to 4 wt.-%, 0.8 to 3 wt.-%, such as for instance in the range from 1 to 5 wt.-%, from 1 to 3 wt.-%, from 1 to 2.5 wt.-% or from 1 .5 to 2.5 wt.-%, based on the total weight of the composition.

[0033] In all embodiments of the present invention, the amount of ethylhexyl triazone in the compositions according to the present invention is advantageously selected in the range from 0.4 to 5 wt.-%., preferably in the range from 0.4 to 4 wt.-%, 0.4 to 3 wt.-%, 0.5 to 3 wt.-%, 0.8 to 5 wt.-%, 0.8 to 4 wt.-%, 0.8 to 3 wt.-%, 0.8 to 2 wt.-%, 0.8 to 1 wt.-%, , such as for instance in the range from 1 to 5 wt.-%, from 1 to 3 wt.-%, from 1 to 2.5 wt.-% or from 1 .5 to 2.5 wt.-%, based on the total weight of the composition.

[0034] In all embodiments of the present invention, the amount of diethylhexyl butamido triazone in the compositions according to the present invention is advantageously selected in the range from 0.4 to 10 wt.-%., preferably in the range from 0.4 to 9 wt.- %, 0.4 to 8 wt.-%, 0.4 to 7 wt.-%, 0.4 to 6 wt.-%, 0.4 to 5 wt.-%, 0.4 to 4 wt.-%, 0.4 to

[0035] 3 wt.-%, 0.5 to 3 wt.-%, 0.8 to 9 wt.-%, 0.8 to 8 wt.-%, 0.8 to 7 wt.-%, 0.8 to 6 wt.-%, 0.8 to 5 wt.-%, 0.8 to 4 wt.-%, 0.8 to 3 wt.-%, such as for instance in the range from 1 to 5 wt.-%, from 1 to 3 wt.-%, or from 1 .5 to 3 wt.-%, based on the total weight of the composition.

[0036] In all embodiments of the present invention, the amount of methylene bisbenzotriazolyl tetramethylbutylphenol (based on a dispersion of approx. 45 -55 wt.-% of MBBT as commercially available e.g. under the tradename PARSOL MAX) in the compositions according to the present invention is advantageously selected in the range from 0.5 to 10 wt.-%, preferably in the range from 1 to 10 wt.-%, more preferably in the range from 2 to 10 wt.-%, most preferably in the range from 2 to 6 wt.-% or from 3 to 6 wt.-%, based on the total weight of the composition.

[0037] In all embodiments of the present invention, the amount of butyl methoxydibenzoylmethane in the compositions according to the present invention is advantageously selected in the range from 0.4 to 5 wt.-%., preferably in the range from 0.4 to 5 wt.-%, 0.4 to 4 wt.-%, 0.4 to 3 wt.-%, 0.5 to 3 wt.-%, 0.8 to 5 wt.-%, 0.8 to 4 wt.-%, 0.8 to 3 wt.-%, such as for instance in the range from 1 to 5 wt.-%, from 2 to

[0038] 5 wt.-%, from 3 to 5 wt.-% or from 3.5 to 5 wt.-%, based on the total weight of the composition.

[0039] In all embodiments of the present invention, the amount of diethylamino hydroxybenzoyl hexyl benzoate in the compositions according to the present invention is advantageously selected in the range from 0.5 to 10 wt.-%., preferably in the range from 0.5 to 9 wt.-%, 0.5 to 8 wt.-%, 0.5 to 7 wt.-%, 0.5 to 6 wt.-%, 0.5 to 5 wt.-%, 0.5 to 4 wt.-%, 0.5 to 3 wt.-%, 1 to 10 wt.-%, 1 to 9 wt.-%, 1 to 8 wt.-%, 1 to 7 wt.-%, 1 to

[0040] 6 wt.-%, 1 to 5 wt.-%, 2 to 5 wt.-%, 3 to 5 wt.-%, such as for instance in the range from 2.5 to 6 wt.-%, from 3 to 6 wt.-%, from 4 to 6 wt.-% or from 3.5 to 5.5 wt.-%, based on the total weight of the composition.

[0041] Particularly preferred organic UV-filter combinations in all embodiments of the present invention encompass the combination of at least two UV filters chosen in the group consisting of DHHB, EHT, BEMT, OMC, polysilicone-15, DBT and MBBT, BMDBM, EHS, OC and BEMT, and mixtures thereof. In one preferred embodiment, the compositions according to the present invention only comprise organic UV-filters.

[0042] In another preferred embodiment, the compositions further comprise one or more inorganic UV-filter.

[0043] The term ‘inorganic UV-filter’ as used herein refers to any metal oxide particles having UV-filter properties as defined above and are thus useful for incorporation into compositions as UV filters. Such inorganic UV-filters are well known to a person skilled in the art and are often referred to as micronized or microfine UV filters such as in particular micronized or microfine titanium dioxide and zinc oxide.

[0044] The particle size of such inorganic UV-filter is not particularly limited. In general, suitable (primary) particle sizes for an efficient UV-light absorption are selected in the range of 2 to 200 nm.

[0045] In all embodiments of the present invention, the (total) amount of the inorganic UV- filters in the compositions according to the present invention is preferably selected in the range from 0.5 to 30 wt.-%, more preferably in the range from 1 to 30 wt.-%, and most preferably in the range from 2 to 30 wt.-%, based on the total weight of the composition. Further suitable amounts are selected in the range from 1 to 25 wt.-%, 1 to 20 wt.-%, 1 to 15 wt.-%, 3.0 to 25 wt.-%, 4 to 25 wt.-%, 5 to 20 wt.-% or 10 to 25 wt.-%.

[0046] Even more advantageously, the (total) amount of inorganic titanium dioxide UV-filters in the compositions according to the present invention is selected in the range of 0.5 to 15 wt.-%, preferably in the range of 1 to 15 wt.-%, more preferably in the range of 2 to 10 wt.-%, most preferably in the range of 2 to 6 wt.-% or 3 to 6 wt.-%, based on the total weight of the composition.

[0047] Even more advantageously, the (total) amount of inorganic zinc oxide UV-filters in the compositions according to the present invention is selected in the range of 0.5 to 25 wt. %, preferably in the range of 1 to 20 wt.-%, more preferably in the range of 2 to 20 wt.-%, most preferably in the range of 5 to 20 wt.-% or 7.5 to 20 wt.-%, based on the total weight of the composition.

[0048] Preferably, if present in the compositions according to the present invention the ratio (w / w) of the titanium dioxide UV-filter(s) to the zinc oxide UV-filter(s) is selected in the range from 1 :5 to 5:1 , preferably from 1 :2 to 2:1 . Even more preferably the amount of zinc oxide in the compositions according to the present invention is higher than the amount of titanium dioxide such as in the range of 5: 1 to 1 .25: 1 , most preferably in the range of 2.5:1 to 1.25:1.

[0049] In one particular embodiment it is preferred that the compositions according to the present invention comprise solely inorganic UV filters.

[0050] According to an embodiment, it is advantageous that the inorganic UV-filters are surface-coated. The surface coating may comprise providing the metal oxide particles with a thin hydrophilic or hydrophobic inorganic or organic layer by methods known per se. According to the present invention the different surface coatings can also comprise water. As a result of the surface treatment, the metal oxide is given a hydrophilic, amphiphilic or hydrophobic character.

[0051] Examples of inorganic surface coatings which are suitable for the purposes of the instant invention comprise aluminum oxide (AI2O3), aluminum hydroxide AI(OH)3, aluminum oxide hydrate (also: Alumina, CAS-No.: 1333-84-2), sodium hexametaphosphate (NaPO3)e, sodium meta-phosphate (NaPO3)n, silicon dioxide (SiO2) (also: Silica, CAS-No.: 7631 -86-9), and iron oxide (Fe2O3). These inorganic surface coatings can be present on their own, in combination and / or in combination with organic coating materials, in particular as outlined below.

[0052] Examples of organic surface coatings which are suitable for use in the present invention include vegetable or animal aluminum stearate, fatty acids such as stearic acid and lauric acid, dimethylpolysiloxane (also: dimethicone), methylpolysiloxane (methicone), simethicone, trimethoxycaprylylsilane, triethoxycaprylylsilane, octyltrimethoxysilane and cetyl phosphates such as potassium cetyl phosphate as well as any mixtures thereof. These organic surface coatings can be present on their own, in combination and / or in combination with inorganic coating materials.

[0053] The crystalline form of the titanium dioxide may be of any crystal or amorphous type. For example, titanium dioxide may be any type of amorphous, rutil, anastase, brookite or a mixture thereof. Preferably, in all embodiments of the present invention, the crystalline form of the titanium dioxide is rutil.

[0054] It is furthermore preferred that the zinc oxide is a white powder consisting of zinc oxide present as wurtzite crystal structures.

[0055] Titanium dioxide UV-filters for use according to an embodiment of the present invention including any pre-dispersions thereof are e.g. available as PARSOL® TX (INCI: titanium dioxide, silica, dimethicone) at DSM Nutritional Products Ltd., Micro Titanium dioxide MT-01 at Tayca or TTO-551 at Ishihara Sangyo Kaisha. Also suitable is double coated titanium dioxide having an inner alumina coating and an outer simethicone coating e.g. commercially available as Eusolex T-2000 at EMD chemicals Inc. / Rona.

[0056] Zinc oxide UV-filters for use according to an embodiment of the present invention including any pre-dispersions thereof are e.g. available from BASF as Z-Cote or Z- Cote HP1 (2% dimethicone coating), from Tayca as MZ-505S (5% methicone coating), or from DSM Nutritional Products Ltd as PARSOL® ZX (2-3.5% triethoxycaprylylsilane coating).

[0057] In a particular embodiment the compositions according to the present invention comprise as inorganic UV-filters at least one double coated titanium dioxide and at least one coated zinc oxide, most preferably in the absence of any further microfine metal oxides (i.e. one double coated titanium dioxide and one coated zinc oxide).

[0058] Most preferably in all embodiments according to the present invention the titanium dioxide UV-filter is either a double coated titanium dioxide, even more preferably a double coated titanium dioxide having an inner silica and an outer organic coating or a silica coated titanium dioxide.

[0059] Preferably, the inner silica coating layer of the double coated titanium dioxide consists of a minimum of 0.5 wt.-% of inorganic silica (based on titanium dioxide). More, preferably the inner coating layer consists of 0.5 wt.-% to 50 wt.-%, most preferably of 1 wt.-% to 20 wt.-% of inorganic silica (based on titanium dioxide).

[0060] The outer coating of the double coated titanium dioxide is preferably selected from the class of organic coatings such e.g. silicone oils (e.g. simethicones, methicones, dimethicones, polysilicone-15), alkyl silanes (e.g. octyl tri(m)ethoxy silane), olefinic acids (e.g. stearic acid), or polyols (e.g. glycerol) and can be applied to the titanium dioxide particle by methods known to a person skilled in the art e.g. described in FI57124. Preferably the outer coating is selected from the group consisting of simethicone, methicone, dimethicone, polysilicones-15, stearic acid and octyl trimethoxy silane. Most preferably the outer coating is dimethicone. Even more preferably, the amount of the outer coating layer is at least 0.25 wt.-% based on the titanium dioxide. Preferably the amount of the outer coating is selected in the range of 0.5 wt.-% to 50 wt.-%, most preferably in the range of 0.5 wt.-% to 10 wt.-%, based on the titanium dioxide.

[0061] In all embodiments of the present invention, the double coated titanium dioxide according to the present invention preferably has a titanium dioxide content selected in the range of 70-95 wt.-% and a silicon dioxide content selected in the range of 5-20 wt.-%, such as preferable a titanium dioxide content selected in the range of 80-90 wt.-% and a silicon dioxide content selected in the range of 10 to 15 wt.-%, with the proviso that the total content of titanium dioxide and silicone dioxide is selected in the range of 90 - 100 wt.-%.

[0062] Preferably, the double coated titanium dioxide has a mean primary particle size in the range from 2 to 100 nm, more preferably in the range of 5 to 50 nm, most preferably in the range of 10 to 25 nm and a secondary particle size between 0.025 and 1 pm, such as preferably between 0.05 and 0.075 pm. Particularly suitable double coated titanium dioxide according to the present invention contains a rutil-type titanium dioxide (TiC ) core with a double coating of silica (inner coating) and dimethicone (outer coating) and has titanium dioxide content of at least 75 wt.-%, preferably in the range from 78-83 wt.-% and a silicon dioxide content of at least 10 wt.-%, preferably in the range from 10.5 to 14.5 wt.-%, and a mean particle size distribution Dn50 of 25 to 100 nm, preferably 40 to 80 nm (analysed by Laser diffraction measurements with a Malvern Mastersizer 2000), which double coated titanium dioxide is e.g. commercially available as PARSOL® TX (INCI: titanium dioxide, silica, dimethicone) at DSM nutritional products Ltd.

[0063] Most preferably, in all embodiments according to the present invention, the zinc oxide is either uncoated or coated with triethoxycaprylylsilane. Most preferably, the zinc oxide is a white powder consisting of zinc oxide present as wurtzite crystal structures, coated with triethoxycaprylylsilane, which has a zinc oxide content of 96-98%, a triethoxycaprylylsilane content of 2-3.5 % and a mean particle size of 90 to 130 nm (analysed by Laser diffraction measurements with a Malvern Mastersizer 2000) which is commercially available as PARSOL® ZX from DSM Nutritional Products Ltd.

[0064] If nothing else is stated in this specification any given parts and percentages are per weight and based on the total weight of the composition.

[0065] Cooling compound

[0066] A “cooling compound” refers to a compound that modulates the TRPM8 receptor.

[0067] Exemplary cooling compounds include, but are not limited to, menthol, cubebol, N- ethyl-p-menthyl-3-carboxamide, isopulegol, 3-(L-menthoxy) propane-1 ,2-diol, cis / trans-p-menthane-3,8-diol, 3-(L-menthoxy)-2-methylpropane-1 ,2-diol, 2-[2-(p- menthan-3-yloxy)ethoxy]ethanol, menthoxyethanol, (1 R,2R,4R)-1 -(2-hydroxy-4- methylcyclohexyl)-ethenone, (1 R,2R,5R)-N-ethyl-5-methyl-2-(prop-1 -en-2-yl)- cyclohexanecarboxamide, N-(3-hydroxy-4-methoxyphenyl)-2-isopropyl-5,5-dimethyl- cyclohexanecarboxamide, N-[4-(cyanomethyl)phenyl]-2-isopropyl-5,5-dimethyl- cyclohexanecarboxamide, N-(2-Hydroxy-2-phenylethyl)-2-isopropyl-5,5-dimethyl- cyclohexane-1 -carboxamide, L-menthol lactate, (-)-menthyl ethylene glycol carbonate, (-)-menthone 1 ,2-glycerol ketal, D / L-menthone 1 ,2-glycerol ketal, (-)-menthyl 1- propylene glycol carbonate, (-)-menthyl 2-propylene glycol carbonate, D / L-menthyl 1- propylene glycol carbonate, D / L-menthyl 2-propylene glycol carbonate, (1 R,2S,5R)- N-(4-methoxyphenyl)-5-methyl-2-(L-methylethyl)cyclohexanecarboxamide, menthyl ethylamido oxalate, (E)-3-benzo[1 ,3]dioxol-5-yl-N,N-diphenyl-2-propenamide, 3,4- methylenedioxycinnamic acid, N,N-diphenylamide, N,N-dimethyl (-)-menthyl succinimide, (1 R,2S,5R)-N-(4-(carbamoylmethyl)phenyl)-menthylcarboxamide, (-)- menthyl pyrrolidone carboxylate, L-phenylephrine p-menthane carboxamide, (1 R,2S,5R)-N-(4-(cyanomethyl)-phenyl)menthylcarboxamide, (1 R,2S,5R)-N-(2- (pyridin-2-yl)ethyl)menthylcarboxamide, 6-isopropyl-3,9-dimethyl-1 ,4- dioxaspiro[4.5]decan-2-one, (1 R,2R,4S)-dihydroumbellulol, N-ethyl-p-menthane-3- carboxamide, 2-isopropyl-N,2,3-trimethylbutyramide, ethyl 3-(p-menthane-3- carboxamido)acetate, N-ethyl-2,2-diisopropylbutanamide, N-(1 ,1 -dimethyl-2- hydroxyethyl)-2,2-diethylbutanamide, N-cyclopropyl-5-methyl-2-isopropyl- cyclohexanecarboxamide, (-)-menthyl acetoacetate, (-)-menthyl succinate, (-)- menthyl (S)-3-hydroxybutyrate, (-)-menthyl glutarate, 1 -[2-hydroxyphenyl]-4-[2- nitrophenyl]-1 ,2,3,6-tetrahydropyrimidine-2-one, di-(-)-menthyl glutarate, N-(2- hydroxyethyl)-2,3-dimethyl-2-isopropylbutanamide, or any combination thereof.

[0068] Further exemplary cooling compounds include, but are not limited to, any cooling compound set forth in WO 2021 / 074281 , such as, for example, (2-(4-phenyl-1 H- im idazol-2-yl )piperid in-1 -yl)( 1 ,2,3-thiadiazol-5-yl)methanone, (2-(4-phenyl-1 H- imidazol-2-yl)piperidin-1 -yl)(thietan-3-yl)methanone, (2,2-dimethylcyclopropyl)(2-(4- phenyl-1 H-imidazol-2-yl)piperidin-1 -yl)methanone, (2- ethoxycyclopropyl)(2-(4- phenyl-1 H-imidazol-2-yl)piperidin-1 -yl)methanone, (2- methoxycyclopropyl)(2-(4- phenyl-1 H-imidazol-2-yl)piperidin-1 -yl)methanone, (2-methylcyclopropyl)(2-(4- phenyl-1 H-imidazol-2-yl)piperidin-1 -yl)methanone, (2S)-2-methyl-1 -(2-(5-(p-tolyl)-1 H- im idazol-2-yl )piperid in-1 -yl)butan-1 -one, (5- methyltetrahydrofuran-3-yl)(2-(4-phenyl- 1 H-imidazol-2-yl)piperidin-1 -yl)methanone, (E)-1 -(2-(5-(3,4-difluorophenyl)-1 H- im idazol-2-yl )piperid in-1 -yl)-2-methylbut-2-en-1 -one, (E)-2-methyl-1 -(2-(5-(p-tolyl)- 1 H-imidazol-2-yl)piperidin-1 -yl)but-2-en-1 -one, (E)-2-methyl-1 -(2-(5-(p-tolyl)-1 H- im idazol-2-yl )piperid in-1 -yl)pent-3-en-1 -one, (R)-2-(methylthio)-1 -((R)-2-(5-(p-tolyl)- 1 H-imidazol-2-yl)piperidin-1 -yl)propan-1 -one, (S)-2-(methylthio)-1 -((R)-2-(5-(p-tolyl)- 1 H-imidazol-2-yl)piperidin-1 -yl)propan-1 -one, (S)-2-(methylthio)-1 -((S)-2-(5-(p-tolyl)- 1 H-im idazol-2-y l)piperidin-1 -yl)propan-1 -one, (S)-2-methyl-1 -((R)-2-(5-(p-toly l)-1 H- im idazol-2-yl )piperid in-1 -yl)butan-1 -one, (tetrahydrofuran-3-yl)(2-(5-(p-tolyl)-1 H- im idazol-2-yl )piperid in-1 -yl)methanone, 1 -(2-(1 H-benzo[d]imidazol-2-yl)piperidin-1 - yl)-2-(methylthio)propan-1 -one, 1 -(2-(4-(1 -methyl-1 H- pyrazol-4-yl)-1 H-imidazol-2 - y l)pi perid in-1 -yl)-2-(methylthio)propan-1 -one, 1 -(2-(4-(2,2- difluorobenzo[d][1 , 3]d ioxol-5-y l)-1 H-imidazol-2-yl)piperidin-1 -yl)-2- (methylthio)propan-l one, 1 -(2-(4-(2,3-dihydrobenzofuran-5-yl)-1 H-imidazol-2- yl)piperidin-1 -yl)-2-(methylthio)propan-1 -one, 1 -(2-(4-(2,3-dihydrobenzofuran-6-yl)- 1 H-imidazol-2-yl)piperidin-1 -yl)-2-(methylthio)propan-1 -one, 1 -(2-(4-(2,5- dimethylphenyl)-1 H-imidazol-2-yl)piperidin-1 -yl)-2-(methylthio)propan-1 -one, 1 -(2-(4- (2-chlorophenyl)-1 H-imidazol-2- yl)piperidin-1 -yl)-2-(methylthio)propan-1 -one, 1 -(2- (4-(2-cyclopropyloxazol-5-yl)-1 H-imidazol-2-yl)piperidin-1 -yl)-2-(methylthio)propan-1 - one, 1 -(2-(4-(2-fluorophenyl)-1 H-imidazol-2 -yl)piperidin-1 -yl)-2-(methylthio)propan-1 - one, 1 -(2-(4-(2-hydroxyphenyl)-1 H-imidazol-2 -yl)piperid in-1 -yl)-2-(methylthio)propan- 1 -one, 1 -(2-(4-(3- ((dimethylamino)methyl)phenyl)-1 H-imidazol-2 -yl)piperidin-1 -yl)-2- (methylthio)propan-l - one, 1 -(2-(4-(3,5-difluorophenyl)-1 H-imidazol-2 -yl)piperidin-1 - yl)-2-(methylthio)propan- 1 -one, 1 -(2-(4-(3,5-dimethylisoxazol-4-yl)-1 H-imidazol-2 - yl)pi perid in-1 -yl)-2- (methylthio)propan-l -one, 1 -(2-(4-(3-chloro-4-methylphenyl)-1 H- imidazol-2-yl)piperidin- 1 -yl)-2-(methylthio)propan-1 -one, 1 -(2-(4-(3-methylfuran-2-yl)- 1 H-imidazol-2 -yl)pi perid in-1 -yl)-2-(methylthio)propan-1 -one, 1 -(2-(4-(4-((1 , 1 - dioxidothiomorpholino)methyl)phenyl)-1 H-imidazol-2-yl)piperidin-1 -yl)-2- (methylthio)propan-l -one, 1 -(2-(4-(4-(1 -hydroxyethyl)phenyl)-1 H-imidazol-2- yl)pi perid in-1 -yl)-2-(methylthio)propan-1 -one, 1 -(2-(4-(4-(difluoromethoxy)-3- fluorophenyl)-1 H- im idazol-2-y l)piperidin-1 -yl)-2-(methylthio)propan-1 -one, 1 -(2-(4-(4- (difluoromethyl)thiophen-3-yl)-1 H-imidazol-2 -yl)piperidin-1 -yl)-2-(methylthio)propan-

[0069] 1 -one, 1 -(2-(4-(4-(methylsulfonyl)phenyl)-1 H-imidazol-2 -yl)piperidin-1 -yl)-2-

[0070] (methylthio)propan-l -one, 1 -(2-(4-(4-(tert-butyl)phenyl)-1 H-imidazol-2 -yl)pi perid in-1 - yl)-2-(methylthio)propan-1 -one, 1 -(2-(4-(4-cyclobutylphenyl)-1 H-imidazol-2- yl)pi perid in-1 -yl)-2-(methylthio)propan-1 -one, 1 -(2-(4-(4-cyclopropyl-2-fluorophenyl)- 1 H-imidazol-2 -yl)pi perid in-1 -yl)-2-(methylthio)propan-1 -one, 1 -(2-(4-(4-fluorophenyl)- 1 H-imidazol-2- y l)piperidin-1 -yl)-2-(methylthio)propan-1 -one, 1 -(2-(4-(4- hydroxyphenyl)-1 H-imidazol-2- y l)piperidin-1 -yl)-2-(methylthio)propan-1 -one, 1 -(2-(4- (4-isopropylphenyl)-1 H-imidazol-2- y l)piperidin-1 -yl)-2-(methylthio)propan-1 -one, 1 - (2-(4-(4-methyl-3-(trifluoromethyl)phenyl)-1 H-imidazol-2 -yl)piperidin-1 -yl)-2- (methylthio)propan-l -one, 1 -(2-(4-(5-((dimethylamino)methyl)thiophen-2-yl)-1 H- im idazol-2-yl )piperid in-1 -yl)-2-(methylthio)propan-1 -one, 1 -(2-(4-(5-methylfuran-2-yl)- 1 H-imidazol-2-yl)piperidin-1 -yl)-2-(methylthio)propan-1 -one, 1 -(2-(4-(5-methylpyridin- 3-yl)-1 H-imidazol-2-yl)piperidin-1 -yl)-2-(methylthio)propan-1 -one, 1 -(2-(4-(6- m ethy lpyridin-3-y l)-1 H-imidazol-2-yl)piperidin- 1 -yl)-2-(methylthio)propan-1 -one, 1 -(2- (4-(benzo[b]thiophen-6-yl)-1 H-imidazol-2-yl)piperidin-1 -yl)-2-(methylthio)propan-1 - one, 1 -(2-(4-methyl-5-phenyl-1 H-imidazol-2-yl)piperidin-1 -yl)-2-(methylthio)propan-1 - one, 1 -(2-(4-phenyl-1 H-imidazol-2-yl)piperidin-1 -yl)-2-((trifluoromethyl)thio)ethan-1 - one, 1 -(2-(4-phenyl-1 H-imidazol-2-yl)piperidin-1 -yl)butan-1 -one, 1 -(2-(4-phenyl-1 H- im idazol-2-yl )piperid in-1 -yl)hexa-3,5-dien-1 -one, 1 -(2-(4-phenyl-1 H-imidazol-2- yl)piperidin-1 -yl)pent-4-en-1 -one, 1 -(2-(4-phenyl-1 H- im idazol-2-y l)piperidin-1 - yl)propan-1 -one, 1 -(2-(5-(2,3-difluorophenyl)-1 H-imidazol-2-yl)piperidin-1 -yl)-2- (methylthio)propan-l -one, 1 -(2-(5-(2,4-difluorophenyl)-1 H-imidazol-2-yl)piperidin-1 - yl)-2-(methylthio)propan-1 -one, 1 -(2-(5-(2,5-difluorophenyl)-1 H-imidazol-2- y l)pi perid in-1 -yl)-2-(methylthio)propan-1 -one, 1 -(2-(5-(2-fluoro-4-methoxyphenyl)-1 H- im idazol-2-yl )piperid in-1 -yl)-2-(methylthio)propan-1 -one, 1 -(2-(5-(2-fluoro-4- methylphenyl)-1 H-imidazol-2-yl)piperidin-1 -yl)-2-(methylthio)propan-1 -one, 1 -(2-(5- (2-methoxypyrimidin-5-yl)-1 H-imidazol-2-yl)piperidin-1 -yl)-2-(methylthio)propan-1 - one, 1 -(2-(5-(3-(methylamino)phenyl)-1 H-imidazol-2-yl)piperidin-1 -yl)-2-

[0071] (methylthio)propan-l -one, 1 -(2-(5-(3,4-difluorophenyl)-1 H-imidazol-2-yl)piperidin-1 - yl)-2-(methylthio)propan-1 -one, 1 -(2-(5-(3,4-difluorophenyl)-1 H-imidazol-2- yl)piperidin-1 -yl)-2-methylbut-3-en-1 -one, 1 -(2-(5-(3,4-dimethoxyphenyl)-1 H-imidazol- 2-yl)piperid in-1 -yl)-2-(methylthio)propan-1 -one, 1 -(2-(5-(3,4-dimethylphenyl)-1 H- im idazol-2-yl )piperid in-1 -yl)-2-(methylthio)propan-1 -one, 1 -(2-(5-(3-fluoro-4-

[0072] (methoxymethyl)phenyl)-1 H-imidazol-2-yl)piperidin-1 -yl)-2-(methylthio)propan-1 -one, 1 -(2-(5-(3-fluoro-4-methylphenyl)-1 H-imidazol-2-yl)piperidin-1 -yl)-2-

[0073] (methylthio)propan-l -one, 1 -(2-(5-(3-fluorophenyl)-1 H-imidazol-2-yl)piperidin-1 -yl)-2- (methylthio)propan-l -one, 1 -(2-(5-(3-methoxyisothiazol-4-yl)-1 H-imidazol-2- yl)pi perid in-1 -yl)-2-(methylthio)propan-1 -one, 1 -(2-(5-(3-methoxyphenyl)-1 H- im idazol-2-yl )piperid in-1 -yl)-2-(methylthio)propan-1 -one, 1 -(2-(5-(4-

[0074] ((methylamino)methyl)phenyl)-1 H-imidazol-2-yl)piperidin-1 -yl)-2- (methylthio)propan- 1 -one, 1 -(2-(5-(4-(2-methoxyethyl)phenyl)-1 H-imidazol-2-yl)piperidin-1 -yl)-2-

[0075] (methylthio)propan-l -one, 1 -(2-(5-(4-(aminomethyl)phenyl)-1 H-imidazol-2- y I ) pi perid i n- 1 -yl)-2-(methylthio)propan-1 -one, 1 -(2-(5-(4- (dimethylam ino)phenyl)-1 H- im idazol-2-yl )piperid in-1 -yl)-2-(methylthio)propan-1 -one, 1 -(2-(5-(4-

[0076] (hydroxymethyl)phenyl)-1 H-imidazol-2-yl)piperidin-1 -yl)-2-(methylthio)propan-1 -one,

[0077] 1 -(2-(5-(4-acetylphenyl)-1 H-imidazol-2-yl)piperidin-1 -yl)-2-(methylthio)propan-1 -one,

[0078] 1 -(2-(5-(4-aminophenyl)-1 H-imidazol-2-yl)piperidin-1 -yl)-2-(methylthio)propan-1 -one,

[0079] 1 -(2-(5-(4-chloro-3-fluorophenyl)-1 H-imidazol-2-yl)piperidin-1 -yl)-2-

[0080] (methylthio)propan-l -one, 1 -(2-(5-(4-chlorophenyl)-1 H-imidazol-2-yl)piperidin-1 -yl)-2-

[0081] (methylthio)propan-l -one, 1 -(2-(5-(4-ethylphenyl)-1 H-imidazol-2-yl)piperidin-1 -yl)-2-

[0082] (methylthio)propan-l -one, 1 -(2-(5-(4-fluorophenyl)-4H-1 , 2, 4-triazol-3-y l)piperid in-1 - yl)-2-(methylthio)propan-1 -one, 1 -(2-(5-(4-methoxy-2-methylphenyl)-1 H-imidazol-2- y l)pi perid in-1 -yl)-2-(methylthio)propan-1 -one, 1 -(2-(5-(4-methoxyphenyl)-1 H- im idazol-2-yl )piperid in-1 -yl)-2-(methylthio)propan-1 -one, 1 -(2-(5-(4-methyl-6- (methy Ith io)pyrid in-3-yl )-1 H-imidazol-2-yl)piperidin-1 -yl)-2-(methylthio)propan-1 -one,

[0083] 1 -(2-(5-(5-(methoxymethyl)thiophen-3-yl)-1 H-imidazol-2-yl)piperidin-1 -yl)-2- (methylthio)propan-l -one, 1 -(2-(5-(6-methoxypyridin-3-yl)-1 H-imidazol-2-yl)piperidin-

[0084] 1 -yl)-2-(methylthio)propan-1 -one, 1 -(2-(5-(benzo[d][1 , 3]dioxol-5-y l)-1 H-imidazol-2- y l)piperidin-1 -yl)-2-(methylthio)propan-1 -one, 1 -(2-(5-(p-tolyl)-1 H-imidazol-2- yl)piperidin-1 -yl)propan-1 -one, 1 -(2-(5-benzyl-1 H-imidazol-2-yl)piperidin-1 -yl)-2- (methylthio)propan-l -one, 1 -(2-(5-bromo-1 H-imidazol-2-yl)piperidin-1 -yl)-2-

[0085] (methylthio)propan-l -one, 2-(2-(1 - (2-(methylthio)propanoyl)piperidin-2-yl)-1 H- imidazol-5-yl)benzonitrile, 2-(2-(4-phenyl- 1 H-imidazol-2-yl)piperidine-1 - carbonyl)cyclopropane-1 -carbonitrile, 2-(5-methylfuran-2-yl)-1 -(2-(4-phenyl-1 H- im idazol-2-yl )piperid in-1 -yl)propan-1 -one, 2-(allylthio)-1 -(2-(5-(p-tolyl)-1 H-imidazol-2- yl)pi perid in-1 -yl)propan-1 -one, 2-(dimethylamino)-1 -(2-(4-phenyl-1 H-imidazol-2- yl)pi perid in-1 -yl)butan-1 -one, 2-(dimethylamino)-1 -(2-(4-phenyl-1 H-imidazol-2- yl)pi perid in-1 -yl)propan-1 -one, 2-(ethylthio)-1 -(2-(5-(p-tolyl)-1 H-imidazol-2- yl)pi perid in-1 -yl)propan-1 -one, 2-(furan-2-yl)-1 -(2-(4-phenyl-1 H-imidazol-2- y l)piperidin-1 -yl)ethan-1 -one, 2-(furan-2-yl)-1 -(2-(4-phenyl-1 H-imidazol-2-yl)piperidin-

[0086] 1 -yl)propan-1 -one, 2-(furan-3-yl)-1 -(2-(4-phenyl-1 H-imidazol-2-yl)piperidin-1 - yl)ethan-1 -one, 2-(furan-3-yl)-1 -(2-(5-(p-tolyl)-1 H-imidazol-2-yl)piperidin-1 -yl)propan-

[0087] 1 -one, 2-(methylamino)-N-(4-(2-(1 -(2-(methylthio)propanoyl)piperidin-2-yl)-1 H- imidazol-5-yl)phenyl)acetamide, 2-(methylsulfinyl)-1 -(2-(5-(p-tolyl)-1 H-imidazol-2- yl)pi perid in-1 -yl)propan-1 -one, 2-(methylsulfonyl)-1 -(2-(4-phenyl-1 H-imidazol-2- yl)pi perid in-1 -yl)ethan-1 -one, 2-(methylsulfonyl)-1 -(2-(4-phenyl-1 H-imidazol-2- yl)pi perid in-1 -yl)propan-1 -one, 2-(methylthio)-1-(2-(2-(p-tolyl)-2H-tetrazol-5- y l)pi perid in-1 -yl)propan-1 -one, 2-(methylthio)-1 -(2-(3-phenyl-1 ,2,4-oxadiazol-5- yl)piperidin-1 -yl)propan-1 -one, 2-(methylthio)-1 -(2-(4-(1 -(trifluoromethyl)-l H-pyrazol- 4-yl)-1 H-imidazol-2-yl)piperidin-1 -yl)propan-1 -one, 2-(methylthio)-1 -(2-(4-(4-

[0088] (morpholinomethyl)phenyl)-1 H-imidazol-2-yl)piperidin-1 -yl)propan-1 -one, 2-

[0089] (methylthio)-l -(2-(4-(5-(trifluoromethyl)furan-2-yl)-1 H-imidazol-2-yl)piperidin-1 - yl)propan-1 -one, 2-(methylthio)-1 -(2-(4-(5-(trifluoromethyl)thiophen-2-yl)-1 H-imidazol- 2-yl)piperid in-1 -yl)propan-1 -one, 2-(methylthio)-1 -(2-(4-(5-methylthiophen-3-yl)-1 H- im idazol-2-yl )piperid in-1 -yl)propan-1 -one, 2-(methylthio)-1 -(2-(4-(m-tolyl)-1 H- im idazol-2-yl )piperid in-1 -yl)propan-1 -one, 2-(methylthio)-1 -(2-(4-(o-tolyl)-1 H-imidazol- 2-yl)piperid in-1 -yl)propan-1 -one, 2-(methylthio)-1 -(2-(4-(pyridin-3-yl)-1 H-imidazol-2- yl)pi perid in-1 -yl)propan-1 -one, 2-(methylthio)-1 -(2-(4-(pyridin-4-yl)-1 H-imidazol-2- yl)pi perid in-1 -yl)propan-1 -one, 2-(methylthio)-1 -(2-(4-(pyrim idin-5-y l)-1 H-imidazol-2- yl)pi perid in-1 -yl)propan-1 -one, 2-(methylthio)-1 -(2-(4-(quinoxalin-6-yl)-1 H-imidazol-2- yl)pi perid in-1 -yl)propan-1 -one, 2-(methylthio)-1 -(2-(4-(thiophen-3-yl)-1 H-imidazol-2- yl)pi perid in-1 -yl)propan-1 -one, 2-(methylthio)-1 -(2-(4-phenyl-1 H-imidazol-2- yl)pi perid in-1 -yl)ethan-1 -one, 2-(methylthio)-1 -(2-(5-(2-(trifluoromethyl)phenyl)-1 H- im idazol-2-yl )piperid in-1 -yl)propan-1 -one, 2-(methylthio)-1 -(2-(5-(2,3,4- trifluorophenyl)-1 H-imidazol-2-yl)piperidin-1 -yl)propan-1 -one, 2-(methylthio)-1 -(2-(5- (2,4,5-trifluorophenyl)-1 H-imidazol-2-yl)piperidin-1 -yl)propan-1 -one, 2-(methylthio)-1 - (2-(5-(3-(trifluoromethyl)phenyl)-1 H-imidazol-2-yl)piperidin-1 -yl)propan-1 -one, 2- (methylthio)-l -(2-(5-(4-(trifluoromethoxy)phenyl)-1 H-imidazol-2-yl)piperidin-1 - yl)propan-1 -one, 2-(methylthio)-1 -(2-(5-(4-(trifluoromethyl)phenyl)-1 H-imidazol-2- y l)piperidin-1 -yl)propan-1 -one, 2-(methylthio)-1 -(2-(5-(4-propylphenyl)-1 H-imidazol-2- y l)piperidin-1 -yl)propan-1 -one, 2-(methylthio)-1 -(2-(5-(4-vinylphenyl)-1 H-imidazol-2- yl)pi perid in-1 -yl)propan-1 -one, 2-(methylthio)-1 -(2-(5-(5-methylthiophen-2-yl)-1 H- im idazol-2-yl )piperid in-1 -yl)propan-1 -one, 2-(methylthio)-1 -(2-(5-(p-tolyl)-1 ,3,4- oxadiazol-2-yl)piperidin-1 -yl)propan-1 -one, 2-(methylthio)-1 -(2-(5-(p-tolyl)-1 H- imidazol-2-yl)azepan-1 -yl)propan-1 -one, 2-(methylthio)-1 -(2-(5-(p-tolyl)-1 H-imidazol- 2-yl)piperidin-1 -yl)propan-1 -one, 2-(methylthio)-1 -(2-(5-(p- to ly l)-4H-1 , 2, 4-triazol-3- yl)pi perid in-1 -yl)propan-1 -one, 2-(methylthio)-1 -(2-(5-(p-tolyl)isoxazol-3-yl)piperidin-

[0090] 1 -yl)propan-1 -one, 2-(methylthio)-1 -(2-(5-(p-tolyl)oxazol-2-yl)piperidin-1 -yl)propan-1 - one, 2-(methylthio)-1 -(2-(5-(p-toly l)thiazol-2-y l)piperid in-1 -yl)propan-1 -one, 2-

[0091] (methylthio)-l -(2-(5-phenyl-1 H-imidazol-2-yl)piperidin-1 -yl)propan-1 -one, 2-

[0092] (methylthio)-l -(2-(5-phenyl-1 H-imidazol-2-yl)pyrrolidin-1 -yl)propan-1 -one, 2- (methy Ith io)-1 -(2-(5-phenyl-4H-1 , 2 , 4-triazol-3-yl )piperid in-1 -yl)propan-1 -one, 2- (methylthio)-l -(2-(5-phenyloxazol-2-yl)piperidin-1 -yl)propan-1 -one, 2-(methylthio)-1 - (4-(5-(p-tolyl)-1 H-imidazol-2-yl)thiazolidin-3-yl)propan-1 -one, 2, 2, 3-trimethy 1-1 -(2-(5- (p-tolyl)-l H-imidazol-2-yl)piperidin-1 -yl)but-3-en-1 -one, 2 ,2 , 3-trim ethyl-1 -(2-(5-(p- tolyl )-1 H-imidazol-2-yl)piperidin-1 -yl)butan-1 -one, 2,2-dimethyl-1 -(2-(5-(p-tolyl)-1 H- im idazol-2-yl )piperid in-1 -yl)but-3-en-1 -one, 2,2-dimethyl-1 -(2-(5-(p-tolyl)-1 H-imidazol- 2-yl)piperidin-1 -yl)butan-1 -one, 2,3-dimethoxy-1 -(2-(4-phenyl-1 H-imidazol-2- yl)piperidin-1 -yl)propan-1 -one, 2,3-dimethyl-1 -(2-(4-phenyl-1 H-imidazol-2- yl)piperidin-1 -yl)butan-1 -one, 2,5-difluoro-4-(2-(1 -(2-(methylthio)propanoyl)piperidin- 2-yl)-1 H-imidazol-4-yl)benzonitrile, 2- amino-1 -(2-(5-(p-tolyl)-1 H-imidazol-2- yl)piperidin-1 -yl)propan-1 -one, 2-cyclobutyl-1 -(2-(4-phenyl-1 H-imidazol-2-yl)piperidin- 1 -yl)propan-1 -one, 2-cyclopentyl-2 -ethoxy-1 -(2-(4-phenyl-1 H-imidazol-2-yl)piperidin- 1 -yl)ethan-1 -one, 2-cyclopropyl-1 -(2-(4-phenyl-1 H-imidazol-2-yl)piperidin-1 -yl)ethan- 1 -one, 2-cyclopropyl-1 -(2-(4-phenyl-1 H-imidazol-2-yl)piperidin-1 -yl)propan-1 -one, 2- cyclopropyl-2-methoxy-1 -(2-(4-phenyl-1 H-imidazol-2-yl)piperidin-1 -yl)ethan-1 -one, 2- ethoxy-1 -(2-(5-(3-fluorophenyl)-1 H-imidazol-2-yl)piperidin-1 -yl)propan-1 -one, 2-ethyl- 1 -(2-(4-phenyl-1 H-imidazol-2-yl)piperidin-1 -yl)but-2-en-1 -one, 2-ethyl-1 -(2-(4-phenyl- 1 H-imidazol-2-yl)piperidin-1 -yl)butan-1 -one, 2-fluoro-4-(2-(1 -(2-

[0093] (methylthio)propanoyl)piperidin-2-yl)-1 H-imidazol-5-yl)benzonitrile, 2-mercapto-1 -(2- (5-(p-tolyl)-1 H-imidazol-2-yl)piperidin-1 -yl)propan-1 -one, 2-methoxy-1 -(2-(4-phenyl- 1 H-imidazol-2-yl)piperidin-1 -yl)butan-1 -one, 2-methoxy-1 -(2-(4-phenyl-1 H-imidazol- 2-yl)piperidin-1 -yl)propan-1 -one, 2-methoxy-1 -(2-(5-(p-tolyl)-1 H-imidazol-2- yl)piperidin-1 -yl)propan-1 -one, 2-methyl-1 -(2-(4-phenyl-1 H-imidazol-2-yl)piperidin-1 - yl)butan-1 -one, 2-methyl-1 -(2-(4-phenyl-1 H-imidazol-2-yl)piperidin-1 -yl)propan-1 - one, 2-methyl-1 -(2-(5-(p-tolyl)-1 H-imidazol-2-yl)piperidin-1 -yl)but-3-en-1 -one, 2- methyl-1 -(2-(5-(p-tolyl)-1 H-imidazol-2-yl)piperidin-1 -yl)butan-1 -one, 2-methyl-1 -(2-(5- (p-tolyl)-l H-imidazol-2-yl)piperidin-1 -yl)butane-1 ,3-dione, 2-methyl-1 -(2-(5-(p-tolyl)- 1 H-imidazol-2-yl)piperidin-1 -yl)pentan-1 -one, 2-methyl-1 -(2-(5-(p-tolyl)-1 H-imidazol- 2-yl)piperidin-1 -yl)prop-2-en-1 -one, 2-methyl-1 -(2-(5-(p-tolyl)-1 H-imidazol-2- yl)piperidin-1 -yl)propan-1 -one, 2-methyl-2-(methylthio)-1 -(2-(5-(p-tolyl)-1 H-imidazol- 2-yl)piperidin-1 -yl)propan-1 -one, 2-methyl-3-(methylthio)-1 -(2-(4-phenyl-1 H-imidazol- 2-yl)piperidin-1 -yl)propan-1 -one, 2-methylene-1 -(2-(5-(p-tolyl)-1 H-imidazol-2- yl)piperidin-1 -yl)butan-1 -one, 3-(2-(1 -(2-(methylthio)propanoyl)piperidin-2-yl)-1 H- imidazol-4-yl)benzonitrile, 3,3,3-trifluoro-2-methyl-1 -(2-(4-phenyl-1 H-imidazol-2- y l)piperidin-1 -yl)propan-1 -one, 3,3,4,4,4-pentafluoro-1 -(2-(4-phenyl-1 H-imidazol-2- yl)piperidin-1 -yl)butan-1 -one, 3, 3-d if luoro-1 -(2-(4-phenyl-1 H-imidazol-2-yl)piperidin-1 - yl)butan-1 -one, 3-fluoro-4-(2-(1 -(2- (methylthio)propanoyl)piperidin-2-yl)-1 H-imidazol- 5-yl)benzonitrile, 3-methyl-1 -(2-(4-phenyl-1 H-imidazol-2-yl)piperidin-1 -yl)but-2-en-1 - one, 3-methyl-1 -(2-(4-phenyl-1 H-imidazol-2-yl)piperidin-1 -yl)butan-1 -one, 4-(2-(1 -(2- (methylthio)propanoyl)piperidin-2-yl)-1 H-imidazol-4-yl)benzonitrile, 4-(2-(1 -(2- (methylthio)propanoyl)piperidin-2-yl)-1 H-imidazol-5-yl)benzaldehyde, 4,4,4-trifluoro- 2-methyl-1 -(2-(4-phenyl-1 H-imidazol-2-yl)piperidin-1 -yl)butan-1 -one, bicyclo[1 .1.1 ]pentan-1 -yl(2-(4-phenyl-1 H-imidazol-2-yl)piperidin-1 -yl)methanone, cyclobutyl(2-(5-(3-fluorophenyl)-1 H-imidazol-2-yl)piperidin-1 -yl)methanone, cyclopentyl(2-(4-phenyl-1 H-imidazol-2-yl)piperidin-1 -yl)methanone, cyclopropyl(2-(4- phenyl-1 H-imidazol-2-yl)piperidin-1 -yl)methanone, methyl 4-(2-(1 -(2- (methylthio)propanoyl)piperidin-2-yl)-1 H-imidazol-5-yl)benzoate, N-(2-hydroxyethyl)- 4-(2-(1 -(2-(methylthio)propanoyl)piperidin-2-yl)-1 H-imidazol-4- yl)benzenesulfonamide, 2-(methylthio)-1 -(2-(5-(3-nitrophenyl)-1 H-imidazol-2- yl)piperidin-1 -yl)propan-1 -one, N-(4-(2-(1 -(2-(methylthio)propanoyl)piperidin-2-yl)-1 H- imidazol-4-yl)phenyl)methane-sulfonamide, 2-(methylthio)-1 -(2-(5-(4-nitrophenyl)-1 H- im idazol-2-yl )piperid in-1 -yl)propan-1 -one, 1 -(sec-buty Isulf iny l)-2-(5-(p-toly l)-1 H- imidazol-2-yl)piperidine, 1 -(sec- butylsulfonyl)-2-(5-(p-tolyl)-1 H-imidazol-2- yl)piperidine, 1 -(isopropylsulfinyl)-2-(5-(p- tolyl)-1 H-imidazol-2-yl)piperidine, 1 -

[0094] (isopropylsulfonyl)-2-(5-(p-tolyl)-1 H-imidazol-2-yl)piperidine, 1 -((1 -

[0095] (methy Ith io)ethyl )su Ifi nyl)-2-(5-(p-tolyl )-1 H-imidazol-2-yl)piperidine, 1 -((1 -

[0096] (methylthio)ethyl)sulfonyl)-2-(5-(p-tolyl)-1 H-imidazol-2-yl)piperidine, 1 -((2-

[0097] (methylthio)propan-2-yl)sulfinyl)-2-(5-(p-tolyl)-1 H-imidazol-2-yl)piperidine, 1 -((2-

[0098] (methylthio)propan-2-yl)sulfonyl)-2-(5-(p-tolyl)-1 H-imidazol-2-yl)piperidine, 1 -(but-3- en- 2-y Isulf inyl )-2-(5-(p-tolyl)-1 H-imidazol-2-yl)piperidine, 1 -(but-3-en-2-ylsulfonyl)-2- (5-(p-tolyl)-1 H-imidazol-2-yl)piperidine, 1 -(pent-3-en-2-ylsulfinyl)-2-(5-(p-tolyl)-1 H- imidazol-2-yl)piperidine, 1 -(pent-3-en-2-ylsulfonyl)-2-(5-(p-tolyl)-1 H-imidazol-2- yl)piperidine, 1 -((2-methylbut-3-en-2-yl)sulfinyl)-2-(5-(p-tolyl)-1 H-imidazol-2- yl)piperidine, 1 -((2-methylbut-3-en-2-yl)sulfonyl)-2-(5-(p-tolyl)-1 H-imidazol-2- yl)piperidine, 1 -(2-(5-(4-(hydroxymethyl)-phenyl)-1 H-imidazol-2-yl)piperidin-1 -yl)-2- methylbutan-1 -one, 2-(methylsulfonyl)-1 -(2-(5-(p-tolyl)-1 H-imidazol-2-yl)piperidin-1 - yl)propan-1 -one, 1 -(4-hydroxy-2-(5-(p-tolyl)-1 H-imidazol-2-yl)piperidin-1 -yl)-2- (methylthio)propan-l -one, 1 -(5-hydroxy-2-(5-(p-tolyl)-1 H-imidazol-2-yl)piperidin-1 -yl)- 2-(methylthio)propan-1-one, 1 -(4-hydroxy-2-(5-(p-tolyl)-1 H-imidazol-2-yl)piperidin-1 - yl)-2-methylbutan-1 -one, 1 -(5-hydroxy-2-(5-(p-tolyl)-1 H-imidazol-2-yl)piperidin-1 -yl)- 2-methylbutan-1 -one, 1 -(2-(5-(4-(hydroxymethyl)phenyl)-1 H-imidazol-2-yl)piperidin-1 - yl)-2-(methylsulfonyl)propan-1 -one, 1 -(4-hydroxy-2-(5-(p- tolyl)-1 H-imidazol-2- y l)pi perid in-1 -yl)-2-(methylsulfonyl)propan-1 -one, 1 -(5-hydroxy-2- (5-(p-tolyl)-1 H- im idazol-2-yl )piperid in-1 -yl)-2-(methylsulfonyl)propan-1 -one, 1 -(2- hydroxy-6-(5-(p- tolyl )-1 H-imidazol-2-yl)piperidin-1 -yl)-2-(methylthio)propan-1 -one, 1 -(2-hydroxy-6-(5- (p-tolyl)-l H-imidazol-2-yl)piperidin-1 -yl)-2-methylbutan-1 -one, 1 -(2-hydroxy-6-(5-(p- tolyl )-1 H-imidazol-2-yl)piperidin-1 -yl)-2-(methylsulfonyl)propan-1 -one, 1 -(3-hydroxy-2- (5-(p-tolyl)-1 H-imidazol-2-yl)piperidin-1 -yl)-2-(methylthio)propan-1 -one, 1 -(3-hydroxy- 2-(5-(p-tolyl)-1 H-imidazol-2-yl)piperidin-1 -yl)-2-methylbutan-1 -one, 1 -(3-hydroxy-2-(5- (p-toly l)-1 H-imidazol-2-yl)piperidin-1 -yl)-2-(methylsulfonyl)propan-1 -one, 1 -(2-(5-(4-

[0099] (hydroxymethyl)phenyl)-1 H-imidazol-2-yl)piperidin-1 -y l)-2-(methy Isulfiny I)- propan-1 - one, 1 -(4-hydroxy-2-(5-(p-tolyl)-1 H-imidazol-2-yl)piperidin-1 -yl)-2-

[0100] (methylsulfinyl)propan-l -one, 1 -(5-hydroxy-2-(5-(p-tolyl)-1 H-imidazol-2-yl)piperidin-1 - yl)-2-(methylsulfinyl)propan-1 -one, 1 -(2-hydroxy-6-(5-(p-tolyl)-1 H-imidazol-2- yl)pi perid in-1 -yl)-2-(methylsulfinyl)propan-1 -one, 1 -(3-hydroxy-2-(5-(p-tolyl)-1 H- im idazol-2-yl )piperid in-1 -yl)-2-(methylsulfinyl)propan-1 -one, 1 -(2-hydroxy-6-(5-(4- (hydroxymethyl)phenyl)-1 H-imidazol-2-yl)piperidin-1 -yl)-2-(methylthio)propan-1 -one, 1 -(5-hydroxy-2-(5-(4-(hydroxymethyl)phenyl)-1 H-imidazol-2-yl)piperidin-1 -yl)-2- (methylthio)propan-l -one, 1 -(4-hydroxy-2-(5-(4-(hydroxymethyl)phenyl)-1 H-imidazol- 2-yl)piperid in-1 -yl)-2-(methylthio)propan-1 -one, 1 -(3-hydroxy-2-(5-(4-

[0101] (hydroxymethyl)- phenyl)-1 H-imidazol-2-yl)piperidin-1 -yl)-2-(methylthio)propan-1 - one, 1 -(2-hydroxy-6-(5-(4-(hydroxymethyl)phenyl)-1 H-imidazol-2-yl)piperidin-1 -yl)-2- methylbutan-1 -one, 1 -(5-hydroxy-2-(5-(4-(hydroxymethyl)phenyl)-1 H-imidazol-2- yl)pi perid in-1 -yl)-2-methylbutan-1 -one, 1 -(4-hydroxy-2-(5-(4-(hydroxymethyl)phenyl)- 1 H-imidazol-2-yl)piperidin-1 -yl)-2-methylbutan-1 -one, 1 -(3-hydroxy-2-(5-(4-

[0102] (hydroxymethyl)phenyl)-1 H-imidazol-2-yl)piperidin-1 -yl)-2-methylbutan-1 -one, 4-(2- (1 -(2-methylbutanoyl)piperidin-2-yl)-1 H-imidazol-5-yl)benzaldehyde, 4-(2-(1 -(2-

[0103] (methylthio)propanoyl)piperidin-2-yl)-1 H-imidazol-5-yl)benzoic acid, 4-(2-(1 -(2- methylbutanoyl)piperidin-2-yl)-1 H-imidazol-5-yl)benzoic acid, (2,2- dimethylcyclopropyl)(2-(5-(p-tolyl)-1 H-imidazol-2-yl)piperidin-1 -yl)methanone, 1 -(2-(5- bromo-1 H-imidazol-2-yl)piperidin-1 -yl)-2-methylbutan-1 -one, 1 -(2-(5-(4- chlorophenyl)-1 H-imidazol-2-yl)piperidin-1 -yl)-2-methylbutan-1 -one, 2-(4-(2-(1 -(2- (methy Ith io)propanoyl )piperid in-2-y l)-1 H-imidazol-5-yl)phenyl)acetonitrile, 2-(4-(2-(1 - (2-methylbutanoyl)piperidin-2-yl)-1 H-imidazol-5-yl)phenyl)acetonitrile, 2-(4-(2-(1 -(2- methylbutanoyl)piperidin-2-yl)-1 H-imidazol-5-yl)phenyl)acetonitrile, 2,3-dimethyl-1 -(2- (5-(p-tolyl)-1 H-imidazol-2-yl)piperidin-1 -yl)butan-1 -one, 2-methyl-1 -(2-(5-(o-toly l)-1 H- im idazol-2-yl )piperid in-1 -yl)butan-1 -one, 2-methyl-1 -(2-(5-(m-tolyl)-1 H-imidazol-2- yl)piperidin-1 -yl)butan-1 -one, 1 -(2-(5-(4-(hydroxymethyl)phenyl)-1 H-imidazol-2- y l)pi perid in-1 -yl)-2-methylbutan-1 -one, 1 -(isopropylsulfonyl)-2-(5-(p-tolyl)-1 H- imidazol-2-yl)piperidine, 1 -(sec-butylsulfonyl)-2-(5-(p-tolyl)-1 H-imidazol-2- yl)piperidine, 2-methyl-1 -(2-(5-(5-methylthiophen-2-yl)-1 H-imidazol-2-yl)piperidin-1 - yl)butan-1 -one, 2-(methylthio)-1 -(2-(5-(p-tolyl)-1 H-imidazol-2-yl)piperazin-1 - yl)propan-1 -one, 2-(methylthio)-1 -(2-(4-(p-tolyl)oxazol-2-yl)piperidin-1 -yl)propan-1 - one, 2-methyl-1 -(2- (4-(p-tolyl)oxazol-2-yl)piperidin-1 -yl)butan-1 -one, or any combination thereof.

[0104] Other exemplary cooling compounds include, but are not limited to, any compound selected from the group consisting of 1 -isopropyl-3,3,5,7- tetramethyloctahydrobenzo[c]isoxazole, 5-(4-fluorophenyl)-1 ,3,3,5,7- pentamethyloctahydrobenzo[c]isoxazole (including (3aR,5R,7S,7aR)-5-(4- fluorophenyl)-1 ,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole, (3aR,5R,7R,7aR)-5- (4-fluorophenyl)-1 ,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole, (3aR,5R,7S,7aS)-5-(4-fluorophenyl)-1 ,3,3,5,7- pentamethyloctahydrobenzo[c]isoxazole, or any combination thereof.

[0105] However, in some embodiments, the coolness-modifying composition may be free of a cooling compound selected from the group consisting of 1 -isopropyl-3,3,5,7- tetramethyloctahydrobenzo[c]isoxazole, 5-(4-fluorophenyl)-1 ,3,3,5,7- pentamethyloctahydrobenzo[c]isoxazole (including (3aR,5R,7S,7aR)-5-(4- fluorophenyl)-1 ,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole, (3aR,5R,7R,7aR)-5- (4-fluorophenyl)-1 ,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole, (3aR,5R,7S,7aS)-5-(4-fluorophenyl)-1 ,3,3,5,7- pentamethyloctahydrobenzo[c]isoxazole, or any combination thereof.

[0106] Other exemplary cooling compounds include, but are not limited to, cooling compounds set forth in WO 2023 / 144326, such as N-Cyclopropyl-2-[(5,6-diphenyl- 1 ,2,4-triazin-3-yl)sulfanyl]propanamide, 2-(5,6-diphenylpyrazin-2-yl)sulfanyl-N- methylpropanamide, 2-[(5,6-diphenyl-1 ,2,4-triazin-3-yl)sulfanyl]-N-methylbutanamide, 2-(5,6-diphenylpyrazin-2-yl)sulfanyl-N-methylacetamide, 2-[(5,6-diphenyl-1 ,2,4- triazin-3-yl)sulfanyl]-N,N-dimethylbutanamide, 1 -(azetidin-1 -yl)-2-[(5,6-diphenyl-1 ,2,4- triazin-3-yl)sulfanyl]ethanone, N-methyl-2-phenanthro[9, 10-e][1 , 2, 4]triazin-3- ylsulfanylpropanamide, 2-[(5,6-diphenyl-1 ,2,4-triazin-3-yl)sulfanyl]-N- methylpropanamide, 2-[[5,6-bis(p-tolyl)-1 ,2,4-triazin-3-yl]sulfanyl]-N-methyl- propanamide, 2-[(5,6-diphenyl-1 ,2,4-triazin-3-yl)sulfanyl]-N,N-dimethylpropanamide, 2-[(5,6-diphenyl-1 ,2,4-triazin-3-yl)sulfanyl]-N-methylacetamide, 2-[(5,6-diphenyl-

[0107] 1 .2.4-triazin-3-y l)su Ifany l]-1 -pyrrol idin-1 -yl-propan-1 -one, N-cyclopropyl-2-[(5,6- diphenyl-1 ,2,4-triazin-3-yl)sulfanyl]acetamide, 2-[[5,6-bis(p-tolyl)-1 , 2, 4-triazin-3- yl]sulfanyl]-N-(2-methoxyethyl)butanamide, N-cyclopentyl-2-[(5,6-diphenyl-1 ,2,4- triazin-3-yl)sulfanyl]propanamide, 2-(5,6-diphenylpyrazin-2-yl)sulfanyl-N,N- dimethylacetamide, N-cyclopropyl-2-(5,6-diphenylpyrazin-2-yl)sulfanylacetamide, 1 - [(5,6-diphenyl-1 ,2,4-triazin-3-yl)sulfanyl]-3-methyl-butan-2-one, 3-[(5,6-diphenyl-

[0108] 1 .2.4-triazin-3-yl)sulfanyl]-N-methylpropanamide, 2-[(5,6-diphenyl-1 ,2,4-triazin-3- yl)sulfanyl]-N,N-dimethylacetamide, 2-[(5,6-diphenyl-1 ,2,4-triazin-3-yl)sulfanyl]-N-(2- furylmethyl)propanamide, 2-[(5,6-diphenyl-1 ,2,4-triazin-3-yl)sulfanyl]pentan-3-one, 3- (2-methoxyethylsulfanyl)-5,6-diphenyl-1 ,2,4-triazine, 3-butylsulfanyl-5,6-diphenyl-

[0109] 1 .2.4-triazine, 2-[(5,6-diphenyl-1 ,2,4-triazin-3-yl)sulfanyl]-N-(tetrahydrofuran-2- ylmethyl)propanamide, 1 -[(5,6-diphenyl-1 ,2,4-triazin-3-yl)sulfanyl]butan-2-one, N- methyl-2 [(5-phenyl-1 ,2,4-triazin-3-yl)sulfanyl]propanamide, 2-[(5,6-diphenyl-1 ,2,4- triazin-3-yl)sulfanyl]-N,N-dimethylethanamine, 3-ethylsulfanyl-5,6-diphenyl-1 ,2,4- triazine, 2-[[5,6-bis(p-tolyl)-1 , 2 , 4-triazin-3-y l]su Ifany l]-1 -pyrrol id in-1 -yl-propan-1 -one, N-cyclohexyl-2-[(5,6-diphenyl-1 ,2,4-triazin-3-yl)sulfanyl]-N-methylpropanamide, 2- [[5,6-bis(4-methoxyphenyl)-1 ,2,4-triazin-3-yl]sulfanyl]-N-methyl-propanamide, methyl N-(5,6-diphenyl-1 ,2,4-triazin-3-yl)carbamate, 2-[(5,6-diphenyl-1 ,2,4-triazin-3-yl)oxy]- N,N-dimethylethanamine, 2-[(5,6-diphenyl-1 ,2,4-triazin-3-yl)amino]-N- methylacetamide, 2-[(5,6-diphenyl-1 ,2,4-triazin-3-yl)sulfanyl]propanoic acid, 2-[[5,6- bis(4-hydroxyphenyl)-1 ,2,4-triazin-3-yl]sulfanyl]-N-methyl-propanamide, 2-[(5,6- dipheny 1-1 ,2,4-triazin-3-yl)sulfanyl]ethanol, N-(5,6-diphenyl-1 , 2, 4-triazin-3- yl)propanamide, 2-[(5,6-diphenyl-1 ,2,4-triazin-3-yl)sulfanyl]-N-(2- thienylmethyl)propanamide, 3-benzylsulfanyl-5,6-diphenyl-1 ,2,4-triazine, N-(2- cyclopropylethyl)-5,6-diphenyl-1 ,2,4-triazin-3-am ine, N-(oxetan-3-yl)-5,6-diphenyl-

[0110] 1 .2.4-triazin-3-amine, 2-[(5,6-diphenyl-1 ,2,4-triazin-3-yl)oxy]-N-methyl-acetamide, N- cyclopropyl-2-[(5,6-diphenyl-1 ,2,4-triazin-3-yl)oxy]acetamide, 3-[(5,6-diphenyl-1 ,2,4- triazin-3-yl)amino]propane-1 ,2-diol, N-(2-methoxyethyl)-5,6-diphenyl-1 ,2,4-triazin-3- amine, (5,6-diphenyl-1 ,2,4-triazin-3-yl)urea, 2-[(5,6-diphenyl-1 ,2,4-triazin-3-yl)oxy]-N- methylpropanamide, 2-[(5,6-diphenyl-1 ,2,4-triazin-3-yl)amino]ethanol, N-methyl-2- pyrazin-2-ylsulfanyl-propanamide, 2-[(5,6-dimethyl-1 ,2,4-triazin-3-yl)sulfanyl]-N- methylpropanamide, 2-[[5,6-bis(3,4-dimethoxyphenyl)-1 ,2,4-triazin-3-yl]sulfanyl]-N- cyclopentyl-butanamide, 2-[[5,6-bis(p-tolyl)-1 ,2,4-triazin-3-yl]sulfanyl]-N-cyclopropyl- acetamide, methyl 2-[(5,6-diphenyl-1 ,2,4-triazin-3-yl)amino]propanoate, 3- methylsulfanyl-5,6-diphenyl-1 , 2, 4-triazine, 2-[(5,6-diphenyl-1 , 2, 4-triazin-3-y l)sulfanyl]- N,3-dimethylbutanamide, N-methyl-2-[[6-phenyl-5-(3-thienyl)-1 ,2,4-triazin-3- yl]sulfanyl]propanamide, 2-[[5,6-bis(3-thienyl)-1 ,2,4-triazin-3-yl]sulfanyl]-N-methyl- propanamide, N-methyl-2-[[6-(m-tolyl)-5-phenyl-1 ,2,4-triazin-3- yl]sulfanyl]propanamide, 2-[(3,6-diphenyl-1 ,2,4-triazin-5-yl)sulfanyl]-N- methylpropanamide, 2-[[5,6-bis(2-thienyl)-1 ,2,4-triazin-3-yl]sulfanyl]-N-methyl- propanamide, 2-[(5,6-diphenyl-1 ,2,4-triazin-3-yl)sulfanyl]-N-methylpentanamide, N- cyclopropyl-2-[(5,6-diphenyl-1 ,2,4-triazin-3-yl)sulfanyl]butanamide, N-cyclopropyl-2- (5,6-diphenylpyrazin-2-yl)sulfanylbutanamide, N-cyclopropyl-2-(5,6-diphenylpyrazin-

[0111] 2-yl)sulfanylpropanamide, 2-[(5,6-Diphenylpyrazin-2-yl)sulfanyl]-N- methylbutanamide, N-methyl-2-[[5-phenyl-6-(3-thienyl)-1 ,2,4-triazin-3- yl]sulfanyl]propanamide, N-methyl-2-[[5-(m-tolyl)-6-phenyl-1 ,2,4-triazin-3- yl]sulfanyl]propanamide, 3-carboxy-3,5-dihydroxy-5-oxopentanoate;2-(4,5- diphenyloxazol-2-yl)sulfanylpropanoylmethyl-ammonium, 2-(4,5-diphenyloxazol-2- yl)sulfanyl-N-methylpropanamide, 2-(4,5-diphenyloxazol-2- yl)sulfanylpropanoylmethylammonium chloride, rac-(1 S,2R)-2-(4,5-diphenyloxazol-2- yl)-N-methylcyclopropanecarboxamide, N-methyl-2-(4-methyl-5-phenyloxazol-2- yl)sulfanylpropanamide, N-cyclopropyl-2-(4,5-diphenyloxazol-2-yl)sulfanylacetamide,

[0112] 3-(4,5-diphenyloxazol-2-yl)-N-ethylpropanamide, 2-methylsulfanyl-1 -[2-[4-(p- tolyl)oxazol-2-yl]-1 -piperidyl]ethenone, 2-(4,5-diphenyloxazol-2-yl)sulfanyl-N- methylbutanamide, N-cyclopropyl-2-(4,5-diphenyloxazol-2-yl)sulfanylpropanamide, 2- [(4,5-diphenyl-1 Himidazol-2-yl)sulfanyl]-N,N-dimethyl-ethanamine, 2-(4,5- diphenyloxazol-2-yl)sulfanyl-N-propylpropanamide, 2-(4,5-diphenyloxazol-2- yl)sulfanyl-N-methylacetamide, 3-(4,5-diphenyloxazol-2-yl)-N-methylpropanamide, 2- (4,5-diphenyloxazol-2-yl)sulfanyl-N-ethylacetamide, N-cyclopropyl-3-(4,5- diphenyloxazol-2-yl)propanamide, 2-(4,5-diphenyloxazol-2-yl)sulfanyl-N-isopropyl- acetamide, 2-(4,5-diphenyloxazol-2-yl)sulfanylpropanamide, 1 -[2-(4,5- diphenyloxazol-2-yl)-1-piperidyl]-2-methylsulfanylethanone, N-cyclopropyl-3-(4,5- diphenyloxazol-2-yl)propanamide, 2-(4,5-diphenyloxazol-2-yl)sulfanyl-N,N-dimethyl- ethanamine, N-[2-(4,5-diphenyloxazol-2-yl)ethyl]acetamide, 2-[4,5-bis(p-tolyl)oxazol- 2-yl]sulfanyl-N-methylpropanamide, 2-(4,5-diphenyloxazol-2-yl)sulfanyl-N-(2- hydroxy-1-methylethyl)acetamide, N-cyclopropyl-2-(4,5-diphenyloxazol-2-yl)sulfanyl- N-methyl-acetamide, 2-(4,5-diphenyloxazol-2-yl)sulfonyl-N-methylpropanamide, 2- (4,5-diphenyloxazol-2-yl)sulfanyl-N,N-diethyl-acetamide, N-cyclopentyl-2-(4,5- diphenyloxazol-2-yl)sulfanylpropanamide, 1-cyclopropyl-3-(4,5-diphenyloxazol-2- yl)propan-1 -one, 3-[4,5-bis(p-tolyl)oxazol-2-yl]-N-methyl-propanamide, N-tert-butyl-2- (4,5-diphenyloxazol-2-yl)sulfanylpropanamide, 3-(4,5-diphenyloxazol-2-yl)-N,N- dimethylpropanamide, (E)-3-(4,5-diphenyloxazol-2-yl)-N-methyl-prop-2-enamide, 4- (4,5-diphenyloxazol-2-yl)-N-methylbutanamide, 2-(4,5-diphenyloxazol-2-yl)sulfanyl- N-isobutylpropanamide, N-cyclopentyl-2-(4,5-diphenyloxazol-2-yl)sulfanylacetamide, rac-(1S,2S)-2-(4,5-diphenyloxazol-2-yl)-N-methylcyclopropanecarboxamide, 1 -(4,5- diphenyloxazol-2-yl)pentan-3-one, 2-(4,5-diphenyloxazol-2-yl)sulfanyl-N-(2- methylcyclohexyl)acetamide, N-cyclobutyl-2-(4,5-diphenyloxazol-2- yl)sulfanylacetamide, 4,5-diphenyl-2-(2-piperidyl)oxazole, N-methyl-3-oxazol-2- ylsulfanylpropanamide, N-(1 ,2-dimethylpropyl)-2-(4,5-diphenyloxazol-2- yl)sulfanylacetamide, 2-[(4,5-diphenyl-1 H-imidazol-2-yl)sulfanyl]-N-methyl- propanamide, 2-(4,5-diphenyloxazol-2-yl)sulfanylpentan-3-one, 3-(4,5- diphenyloxazol-2-yl)sulfanyl-N-methylpropanamide, N-methyl-2-oxazol-2- ylsulfanylpropanamide, 1 -(4,5-diphenyloxazol-2-yl)sulfanyl-3-methylbutan-2-one, 2- (4,5-diphenyloxazol-2-yl)sulfanyl-N-(1-methylbutyl)acetamide, 2-(4,5-diphenyloxazol- 2-yl)sulfanyl-N-(2-methoxyethyl)acetamide, 2-benzylsulfanyl-4,5-diphenyl-oxazole, 2- ethylsulfanyl-4,5-diphenyl-oxazole, N-cyclopropyl-2-[(4,5-dimethyl-1 H-imidazol-2- yl)sulfanyl]propanamide, 2-(4,5-diphenyloxazol-2-yl)sulfanylethylacetate, 2-[4,5-bis(4- methoxyphenyl)oxazol-2-yl]sulfanyl-N-cyclopropylacetamide, N-methyl-2-oxazol-2- ylsulfanylacetamide, 2-(4,5-diphenyloxazol-2-yl)sulfanylethanol, 1 -(4,5- diphenyloxazol-2-yl)sulfanylbutan-2-one, 2-(4,5-diphenyloxazol-2-yl)ethyl- methylammonium chloride, methyl N-[2-(4,5-diphenyloxazol-2-yl)ethyl]carbamate, N- methyl-2-[(5-phenyl-1 H-imidazol-2-yl)sulfanyl]acetamide, 2-(4,5-diphenyloxazol-2- yl)sulfanyl-N-isobutyl-acetamide, N-cyclopropyl-2-oxazol-2-ylsulfanylacetamide, 2- (4,5-diphenyloxazol-2-yl)sulfanyl-N-(2-methoxy-1-methylethyl)acetamide, 2-[4,5- bis(p-tolyl)oxazol-2-yl]sulfanyl-N-methylacetamide, 2-[4,5-bis(4- methoxyphenyl)oxazol-2-yl]sulfanyl-N-methyl-propanamide, N-butyl-2-(4,5- diphenyloxazol-2-yl)sulfanylacetamide, N,N-dimethyl-4,5-diphenyl-oxazol-2-amine, 2- [4,5-bis(4-methoxyphenyl)oxazol-2-yl]sulfanyl-N-methyl-acetamide, methyl 3-(4,5- diphenyloxazol-2-yl)propanoate, and mixtures thereof.

[0113] Preferably, the cooling agent is chosen in the group consisting of N-(1 H-pyrazol-5-yl)- N-(thiophen-2-ylmethyl)-2-(p-tolyloxy)acetamide, menthol, menthyl lactate, N-ethyl-p- menthane-3-carboxamide, 2-isopropyl-N,2,3-trimethylbutyramide, ethyl 3-(p- menthane-3-carboxamido)acetate, N-(Ethoxycarbonylmethyl)-3-p- menthanecarboxamide, isopulegol, cubebol, and mixtures thereof. Most preferably the cooling agent is chosen in the group consisting of: N-(1 H-pyrazol-5-yl)-N- (thiophen-2-ylmethyl)-2-(p-tolyloxy)acetamide, menthol, menthyl lactate, 2-lsopropyl- N,2,3-trimethylbutyramide, and mixtures thereof.

[0114] According to an embodiment, the composition comprises the cooling compound in an amount comprised between 0.01 % and 2%, more preferably between 0.1 % and 1 %, even more preferably between 0.2% and 0.5% based on the total weight of the composition.

[0115] In an embodiment, the composition comprises the cooling compound in an amount of from 0.05% to 0.5%, typically from 0.05% to 0.3%, more typically 0.15% and 0.3%, based on the total weight of the composition.

[0116] Cooling enhancing compound

[0117] As used herein, a “cooling enhancing compound” is capable of enhancing the cooling sensation provided by a cooling compound, such as those described herein, but may also provide a cooling sensation alone. Such cooling enhancing compounds include, but are not limited to, naturally derived compounds, such as menthol or analogs thereof, or synthetic compounds, such as any compounds set forth in U.S. Patent Nos. 9,394,287 and 10,421 ,727. Exemplary cooling enhancing compound include, but are not limited to, N-(1 H-pyrazol- 5-yl)-N-(thiophen-2-ylmethyl)-2-(p-tolyloxy)acetamide, N-ethyl-N-(thiophen-2-ylmethyl)-2-(p-tolyloxy)acetamide, 2-(2,3-dihydro-1 H-inden-5-yloxy)-N-(1 H-pyrazol-3-yl)-N-(thiophen-2- ylmethyl)acetam ide, 2-(2,3-dihydro-1 H-inden-5-yloxy)-N-(4-methyl-1 H-pyrazol-3-yl)-N-(thiophen-2- ylmethyl)acetam ide, 2-(2,3-dihydro-1 H-inden-5-yloxy)-N-(1 H-pyrazol-4-yl)-N-(thiophen-2- ylmethyl)acetam ide, N-(oxazol-2-yl)-N-(thiophen-2-ylmethyl)-2-(p-tolyloxy)acetamide, 2-(2,3-dihydro-1 H-inden-5-yloxy)-N-(3,5-dimethyl-1 H-pyrazol-4-yl)-N-(thiophen-2- ylmethyl)acetam ide, N-(3,5-dimethyl-1 H-pyrazol-4-yl)-N-(thiophen-2-ylmethyl)-2-(p-tolyloxy)acetamide, N-(3-methyl-1 H-pyrazol-4-yl)-N-(thiophen-2-ylmethyl)-2-(p-tolyloxy)acetamide, 2-(benzo[d][1 ,3]dioxol-5-yloxy)-N-(1 H-pyrazol-5-yl)-N-(thiophen-2- ylmethyl)acetam ide, 2-(benzo[d][1 ,3]dioxol-5-yloxy)-N-(3,5-dimethyl-1 H-pyrazol-4-yl)-N-(thiophen-2- ylmethyl)acetam ide, 4-(N-(thiophen-2-ylmethyl)-2-(p-tolyloxy)acetamido)-1 H-pyrazol-2-ium chloride, N-(1 H-pyrazol-4-yl)-N-(thiophen-2-ylmethyl)-2-(p-tolyloxy)acetamide, N-(isoxazol-3-yl)-N-(thiophen-2-ylmethyl)-2-(p-tolyloxy)acetamide, N-(1 -(cyanomethyl)-1 H-pyrazol-3-yl)-N-(thiophen-2-ylmethyl)-2-(p- tolyloxy)acetamide, 2-(benzo[d][1 ,3]dioxol-5-yloxy)-N-(3-methyl-1 H-pyrazol-4-yl)-N-(thiophen-2- ylmethyl)acetam ide, 2-(benzo[d][1 ,3]dioxol-5-yloxy)-N-(1 H-pyrazol-4-yl)-N-(thiophen-2- ylmethyl)acetam ide, N-cyclopropyl-N-(thiophen-2-ylmethyl)-2-(p-tolyloxy)acetamide, N-allyl-N-(thiophen-2-ylmethyl)-2-(p-tolyloxy)acetamide, N-(1 H-pyrazol-4-yl)-N-(thiophen-2-ylmethyl)-3-p-tolylpropanamide, 2-(4-methoxyphenoxy)-N-(1 H-pyrazol-4-yl)-N-(thiophen-2-ylmethyl)acetamide, N-propyl-N-(thiophen-2-ylmethyl)-2-(p-tolyloxy)acetamide, N-allyl-2-(benzo[d][1 ,3]dioxol-5-yloxy)-N-(thiophen-2-ylmethyl)acetamide, 2-(2,3-dihydro-1 H-inden-5-yloxy)-N-(pyridin-3-yl)-N-(thiophen-2-ylmethyl)acetamide, 2-(3-methoxyphenoxy)-N-(1 H-pyrazol-4-yl)-N-(thiophen-2-ylmethyl)acetamide, N-(pyridin-4-yl)-N-(thiophen-2-ylmethyl)-2-(p-tolyloxy)acetamide, N-isopropyl-N-(thiophen-2-ylmethyl)-2-(p-tolyloxy)acetamide,

[0118] N-(bicyclo[2.2.1]heptan-2-ylmethyl)-N-(1 H-pyrazol-3-yl)-2-(p-tolyloxy)acetamide, N-ethyl-N-(thiophen-3-ylmethyl)-2-(p-tolyloxy)acetamide,

[0119] N-(bicyclo[2.2.1]heptan-2-ylmethyl)-N-(1 H-pyrazol-3-yl)-2-(p-tolyloxy)acetamide, 2-phenoxy-N-phenyl-N-(thiophen-2-ylmethyl)acetamide,

[0120] 2-(2,3-dihydro-1 H-inden-5-yloxy)-N-phenyl-N-(thiophen-2-ylmethyl) acetamide, N-(bicyclo[2.2.1]heptan-2-ylmethyl)-3-phenyl-N-(1 H-pyrazol-3-yl) propenamide, N-(pyridin-3-yl)-N-(thiophen-2-ylmethyl)-2-(p-tolyloxy)acetamide, N-ethyl-N-((5-methylthiophen-2-yl)methyl)-2-(p-tolyloxy)acetamide,

[0121] N 2-(4-ethylphenoxy)-N-(pyridin-3-yl)-N-(thiophen-2-ylmethyl)acetamide, N-(1-methyl-1 H-pyrazol-5-yl)-N-(thiophen-2-ylmethyl)-2-(p-tolyloxy)acetamide, N-(bicyclo[2.2.1 ]heptan-2-ylmethyl)-2-phenoxy-N-(1 H-pyrazol-3-yl)acetamide, 2-(benzo[d][1 ,3]dioxol-5-yloxy)-N-(pyridin-3-yl)-N-(thiophen-2-ylmethyl)acetamide,

[0122] N-ethyl-2-(4-fluorophenoxy)-N-(thiophen-2-ylmethyl)acetamide, N-sec-butyl-N-(thiophen-2-ylmethyl)-2-(p-tolyloxy)acetamide,

[0123] 2-(4-chlorophenoxy)-N-phenyl-N-(thiophen-2-ylmethyl)acetamide, N-phenyl-N-(thiazol-2-ylmethyl)-2-(p-tolyloxy)acetamide, N-methyl-N-(thiophen-2-ylmethyl)-2-(p-tolyloxy)acetamide,

[0124] 3-(2-(3-methoxyphenoxy)-N-(thiophen-2-ylmethyl)acetamido)pyridinium chloride, 2-(3-methoxyphenoxy)-N-(pyridin-2-yl)-N-(thiophen-2-ylmethyl)acetamide, 2-(2-isopropyl-5-methylphenoxy)-N-(1 H-pyrazol-3-yl)-N-(thiophen-2- ylmethyl)acetam ide,

[0125] N-((5-chlorothiophen-2-yl)methyl)-N-ethyl-2-(4-methoxyphenoxy)acetamide,

[0126] N-((5-methylthiophen-2-yl)methyl)-N-phenyl-2-(p-tolyloxy)acetamide,

[0127] N-(pyridin-2-yl)-N-(thiophen-2-ylmethyl)-2-(m-tolyloxy)acetamide,

[0128] N-(pyridin-3-yl)-N-(thiophen-2-ylmethyl)-2-(m-tolyloxy)acetamide,

[0129] 2-(3,4-dimethylphenoxy)-N-(pyridin-2-yl)-N-(thiophen-2-ylmethyl)acetamide, 2-(4-ethylphenoxy)-N-(pyridin-2-yl)-N-(thiophen-2-ylmethyl)acetamide, 2-(3-methoxyphenoxy)-N-(pyridin-3-yl)-N-(thiophen-2-ylmethyl)acetamide, N-ethyl-3-phenyl-N-(thiophen-2-ylmethyl)propenamide,

[0130] N-ethyl-N-(thiazol-5-ylmethyl)-2-(p-tolyloxy)acetamide,

[0131] (R) — N-(3-methylbutan-2-yl)-2-(3-nitrophenoxy)acetamide, N-ethyl-2-phenoxy-N-(thiophen-2-ylmethyl)acetamide,

[0132] ((R) — N-(1 -hydroxy-3-methylbutan-2-yl)-N-isopropyl-2-(m-tolyloxy)acetamide,

[0133] N-(4-fluorophenyl)-N-(thiophen-2-ylmethyl)-2-(p-tolyloxy)acetamide,

[0134] 2 3,4,6-trimethyl-N-(pyridin-2-yl)-N-(thiophen-2-ylmethyl)benzofuran-2-carboxamide,

[0135] 2-(4-methoxyphenoxy)-N-(pyridin-3-yl)-N-(thiophen-2-ylmethyl)acetamide,

[0136] 3.5-dimethyl-N-(pyridin-2-yl)-N-(thiophen-2-ylmethyl)benzofuran-2 -carboxamide,

[0137] 2-(3-methoxyphenoxy)-N-(pyridin-2-yl)-N-(thiophen-2-ylmethyl)acetamide,

[0138] N-allyl-2-(2-hydroxyphenoxy)-N-((5-methylthiophen-2-yl)methyl)acetamide,

[0139] N-(pyrazin-2-yl)-N-(thiophen-2-ylmethyl)-2-(p-tolyloxy)acetamide,

[0140] 2-(4-isopropylphenoxy)-N-(pyridin-2-yl)-N-(thiophen-2-ylmethyl)acetamide,

[0141] 2-(4-fluorophenoxy)-N-(pyridin-3-yl)-N-(thiophen-2-ylmethyl)acetamide,

[0142] N-benzyl-N-ethyl-2-(p-tolyloxy)acetamide,

[0143] 2-(4-chlorophenoxy)-N-(pyridin-2-yl)-N-(thiophen-2-ylmethyl)acetamide,

[0144] 2-(4-bromophenoxy)-N-(pyridin-2-yl)-N-(thiophen-2-ylmethyl)acetamide, N-(2-chlorophenyl)-N-(thiophen-2-ylmethyl)-2-(p-tolyloxy)acetamide, 2-(2-isopropyl-5-methylcyclohexyloxy)-N-(2-(pyridin-4-yl)ethyl)acetamide,

[0145] N-(thiazol-2-yl)-N-(thiophen-2-ylmethyl)-2-(p-tolyloxy)acetamide,

[0146] N-(cyclohexylmethyl)-2-(2,4-dimethylphenoxy)-N-(pyridin-2-yl)acetamide,

[0147] N-(furan-2-ylmethyl)-N-(pyridin-2-yl)-2-(p-tolyloxy)acetamide,

[0148] 3.6-dimethyl-N-(pyridin-2-yl)-N-(thiophen-2-ylmethyl)benzofuran-2 -carboxamide, 2-(3-fluorophenoxy)-N-(pyridin-3-yl)-N-(thiophen-2-ylmethyl)acetamide, N-ethyl-N-(thiazol-2-ylmethyl)-2-(p-tolyloxy)acetamide,

[0149] N-ethyl-N-(3-fluorobenzyl)-2-(p-tolyloxy)acetamide,

[0150] 3.5.6-trimethyl-N-(pyridin-2-yl)-N-(thiophen-2-ylmethyl)benzofuran-2-carboxamide,

[0151] N-((5-ethylthiophen-2-yl)methyl)-N-phenyl-2-(p-tolyloxy)acetamide,

[0152] N-((5-ethylthiophen-2-yl)methyl)-N-phenyl-2-(p-tolyloxy)acetamide,

[0153] N-(pyrimidin-2-yl)-N-(thiophen-2-ylmethyl)-2-(p-tolyloxy)acetamide,

[0154] 2-phenoxy-N-(pyridin-3-yl)-N-(thiophen-2-ylmethyl)acetamide,

[0155] 2-(4-fluorophenoxy)-N-(pyridin-2-yl)-N-(thiophen-2-ylmethyl)acetamide, N-(thiophen-2-ylmethyl)butan-1 -amine,

[0156] 2-(3-chlorophenoxy)-N-(pyridin-2-yl)-N-(thiophen-2-ylmethyl)acetamide, N-((3-methylthiophen-2-yl)methyl)-N-phenyl-2-(p-tolyloxy)acetamide, 2-phenoxy-N-(pyridin-2-yl)-N-(thiophen-2-ylmethyl)acetamide, (E)-3-(benzo[d][1 ,3]-dioxol-5-yl)-N-(1 H-pyrazol-5-yl)-N-(thiophen-2- ylmethyl)acrylamide, (E)-N-(5-methyl-1 H-pyrazol-4-yl)-N-(thiophen-2-ylmethyl)-3-p-tolylacrylamide, (E)-N-(1 H-pyrazol-5-yl)-N-(thiophen-2-ylmethyl)-3-p-tolylacrylamide, (E)-N-(1 H-pyrazol-4-yl)-N-(thiophen-2-ylmethyl)-3-p-tolylacrylamide, (E)-3-(benzo[d][1 ,3]dioxol-5-yl)-N-(1 H-pyrazol-4-yl)-N-(thiophen-2- ylmethyl)acrylamide, (E)-N-(3,5-dimethyl-1 H-pyrazol-4-yl)-N-(thiophen-2-ylmethyl)-3-p-tolylacrylamide, (E)-3-(benzo[d][1 ,3]dioxol-5-yl)-N-(5-methyl-1 H-pyrazol-4-yl)-N-(thiophen-2-ylmethyl) acrylamide, (E)-3-(benzo[d][1 ,3]dioxol-5-yl)-N-cyclopropyl-N-(thiophen-2-ylmethyl)acrylamide, (E)-3-(benzo[d][1 ,3]dioxol-5-yl)-N-ethyl-N-(thiophen-2-ylmethyl)acrylamide, (E)-3-(benzo[d][1 ,3]dioxol-5-yl)-N-(3,5-dimethyl-1 H-pyrazol-4-yl)-N-(thiophen-2- ylmethyl)acrylamide, (E)-N-ethyl-N-(thiophen-2-ylmethyl)-3-p-tolylacrylamide, (E)-3-(4-methoxyphenyl)-N-(1 H-pyrazol-4-yl)-N-(thiophen-2-ylmethyl)acrylamide, (E)-3-(4-methoxyphenyl)-N-(1 H-pyrazol-5-yl)-N-(thiophen-2-ylmethyl)acrylamide, N-(1 H-pyrazol-5-yl)-N-(thiophen-2-ylmethyl)-3-p-tolylpropanamide, N-(3,5-dimethyl-1 H-pyrazol-4-yl)-N-(thiophen-2-ylmethyl)cinnam amide, N-(1 H-pyrazol-5-yl)-N-(thiophen-2-ylmethyl)cinnamamide, N-(1 H-pyrazol-4-yl)-N-(thiophen-2-ylmethyl)cinnamamide, (E)-3-(2,3-dihydro-1 H-inden-5-yl)-N-(3,5-dimethyl-1 H-pyrazol-4-yl)-N-(thiophen-2- ylmethyl) acrylamide, ((E)-3-(benzo[d][1 ,3]dioxol-5-yl)-N-(pyridin-3-yl)-N-(thiophen-2-ylmethyl)acrylamide, (+ / -) (E)-2-phenyl-N-(1 H-pyrazol-4-yl)-N-(thiophen-2- ylmethyl)cyclopropanecarboxamide, (E)-3-(benzo[d][1 ,3]dioxol-5-yl)-N-(pyridin-2-yl)-N-(thiophen-2-ylmethyl)acrylamide, 2-phenoxy-N-(1 H-pyrazol-5-yl)-N-(thiophen-2-ylmethyl)acetamide, (E)-3-(2,3-dihydro-1 H-inden-5-yl)-N-(1 H-pyrazol-5-yl)-N-(thiophen-2-ylmethyl) acrylamide, (E)-3-(2,3-dihydro-1 H-inden-5-yl)-N-(5-methyl-1 H-pyrazol-4-yl)-N-(thiophen-2- ylmethyl) acrylamide, N-(bicyclo[2.2.1 ]heptan-2-yl)-N-(1 H-pyrazol-5-yl)cinnamamide, N-ethyl-N-(thiophen-2-ylmethyl)cinnamamide, 2-(2,3-dihydro-1 H-inden-5-yloxy)-N-ethyl-N-(thiazol-5-ylmethyl)acetamide, 2-(2,3-dihydro-1 H-inden-5-yloxy)-N-ethyl-N-(thiazol-5-ylmethyl)acetamide, 2-(benzo[d][1 ,3]dioxol-5-yloxy)-N-phenyl-N-(thiophen-2-ylmethyl)acetamide, N-allyl-N-(thiophen-2-ylmethyl)cinnamamide,

[0157] (+ / -) (E)-N-ethyl-2-phenyl-N-(thiophen-2-ylmethyl)cyclopropanecarboxamide, (E)-N-(bicyclo[2.2.1 ]heptan-2-yl)-N-(1 H-pyrazol-5-yl)-3-p-tolylacrylam ide, N-(bicyclo[2.2.1 ]heptan-2-yl)-2-(2,3-dihydro-1 H-inden-5-yloxy)-N-(1 H-pyrazol-5- yl)acetamide,

[0158] N-(bicyclo[2.2.1 ]hept-5-en-2-ylmethyl)-N-(1 H-pyrazol-5-yl)-2-(p-tolyloxy)acetamide, 2-(cyclohexyloxy)-N-(1 H-pyrazol-5-yl)-N-(thiophen-2-ylmethyl)acetamide, N-(bicyclo[2.2.1 ]heptan-2-yl)-2-(cyclohexyloxy)-N-(1 H-pyrazol-5-yl)acetamide, 3,4,6-trimethyl-N-(pyridin-2-yl)-N-(thiophen-2-ylmethyl)benzofuran-2-carboxamide,

[0159] 2-(2,3-dihydro-1 H-inden-5-yloxy)-N-ethyl-N-((5-methylthiophen-2- yl)methyl)acetamide,

[0160] (E)-N-phenyl-N-(thiophen-2-ylmethyl)-3-p-tolylacrylamide,

[0161] N-phenyl-N-(thiophen-2-ylmethyl)cinnamamide,

[0162] N-(pyridin-2-yl)-N-(thiophen-2-ylmethyl)cinnamamide,

[0163] (+ / -) (E)-N,2-diphenyl-N-(thiophen-2-ylmethyl)cyclopropanecarboxamide,

[0164] 3.5-dimethyl-N-(pyridin-2-yl)-N-(thiophen-2-ylmethyl)benzofuran-2 -carboxamide, N-(bicyclo[2.2.1 ]heptan-2-yl)-N-(1 H-pyrazol-5-yl)-3-p-tolylpropanamide,

[0165] (E)-N-allyl-3-(7-chlorobenzo[d][1 ,3]dioxol-5-yl)-N-(thiophen-2-ylmethyl)acrylamide, N-(pyridin-3-yl)-N-(thiophen-2-ylmethyl)cinnamamide,

[0166] 3.6-dimethyl-N-(pyridin-2-yl)-N-(thiophen-2-ylmethyl)benzofuran-2 -carboxamide, (E)-N-ethyl-3-(4-(imidazo[1 ,2-a]pyridin-2-ylmethoxy)phenyl)-N-(thiophen-2-ylmethyl) acrylamide,

[0167] (E)-3-(benzo[d][1 ,3]dioxol-5-yl)-N,N-bis(thiophen-2-ylmethyl)acrylamide,

[0168] N-(cyclohexylmethyl)-N-ethyl-2-(p-tolyloxy)acetamide,

[0169] 2-(benzo[d][1 ,3]dioxol-5-yloxy)-N-phenyl-N-(thiophen-2-ylmethyl)acetamide, 2-(2,3-dihydro-1 H-inden-5-yloxy)-N-ethyl-N-(thiophen-2-ylmethyl)acetamide, 2-(2-hydroxy-4-methylphenoxy)-N-(1 H-pyrazol-5-yl)-N-(thiophen-2-ylmethyl)- acetamide,

[0170] N-ethyl-2-(2-hydroxy-4-methylphenoxy)-N-(thiophen-2-ylmethyl)acetamide,

[0171] N-phenyl-N-(thiophen-2-ylmethyl)-2-(p-tolyloxy)acetamide, 2-(2,3-dihydrobenzo[b][1 ,4]dioxin-6-yloxy)-N-phenyl-N-(thiophen-2- ylmethyl)acetam ide,

[0172] 2-(3-methoxyphenoxy)-N-phenyl-N-(thiophen-2-ylmethyl)acetamide,

[0173] 2-(4-methoxyphenoxy)-N-phenyl-N-(thiophen-2-ylmethyl)acetamide,

[0174] 2-(4-fluorophenoxy)-N-phenyl-N-(thiophen-2-ylmethyl)acetamide,

[0175] 2-(benzo[d][1 ,3]dioxol-5-yloxy)-N-ethyl-N-(thiophen-2-ylmethyl)acetamide,

[0176] N-ethyl-2-(3-methoxyphenoxy)-N-(thiophen-2-ylmethyl)acetamide,

[0177] N-phenyl-N-(thiophen-2-ylmethyl)-2-(m-tolyloxy)acetamide,

[0178] N-ethyl-N-(furan-3-ylmethyl)-2-(p-tolyloxy)acetamide,

[0179] N-ethyl-2-(4-methoxyphenoxy)-N-(thiophen-2-ylmethyl)acetamide,

[0180] N-ethyl-N-(thiophen-2-ylmethyl)-2-(o-tolyloxy)acetamide,

[0181] 2-(3-fluorophenoxy)-N-phenyl-N-(thiophen-2-ylmethyl)acetamide,

[0182] 2-(benzo[d][1 ,3]dioxol-5-yloxy)-N-ethyl-N-(furan-3-ylmethyl)acetamide,

[0183] N-ethyl-3-(4-methoxyphenyl)-N-(thiophen-2-ylmethyl)propenamide,

[0184] N-ethyl-N-(thiophen-2-ylmethyl)-2-(m-tolyloxy)acetamide,

[0185] N-(pyridin-2-yl)-N-(thiophen-2-ylmethyl)-2-(p-tolyloxy)acetamide,

[0186] N-ethyl-2-(2-hydroxyphenoxy)-N-(thiophen-2-ylmethyl)acetamide,

[0187] 2-(4-ethylphenoxy)-N-phenyl-N-(thiophen-2-ylmethyl)acetamide,

[0188] 2-(3,4-dimethylphenoxy)-N-phenyl-N-(thiophen-2-ylmethyl)acetamide,

[0189] 2-(benzo[d][1 ,3]dioxol-5-yloxy)-N-(pyridin-2-yl)-N-(thiophen-2-ylmethyl)acetamide,

[0190] 2-(3-chlorophenoxy)-N-phenyl-N-(thiophen-2-ylmethyl)acetamide,

[0191] N-ethyl-3-(4-fluorophenyl)-N-(thiophen-2-ylmethyl)propenamide,

[0192] 2-(2-hydroxyphenoxy)-N-phenyl-N-(thiophen-2-ylmethyl)acetamide,

[0193] N-(pyridin-2-yl)-N-(thiophen-2-ylmethyl)-2-(p-tolyloxy)acetamide,

[0194] N-ethyl-N-(furan-2-ylmethyl)-2-(p-tolyloxy)acetamide,

[0195] N-ethyl-N-(thiophen-2-ylmethyl)-3-o-tolylpropanamide,

[0196] 2-(2-fluorophenoxy)-N-phenyl-N-(thiophen-2-ylmethyl)acetamide,

[0197] N-phenyl-N-(thiophen-2-ylmethyl)-2-(o-tolyloxy)acetamide,

[0198] N-ethyl-2-(3-fluorophenoxy)-N-(thiophen-2-ylmethyl)acetamide,

[0199] 2-(benzo[d][1 ,3]dioxol-5-yloxy)-N-ethyl-N-(furan-2-ylmethyl)acetamide,

[0200] 2-(2-chlorophenoxy)-N-phenyl-N-(thiophen-2-ylmethyl)acetamide,

[0201] 2-(4-isopropylphenoxy)-N-phenyl-N-(thiophen-2-ylmethyl)acetamide,

[0202] N-ethyl-3-(3-fluorophenyl)-N-(thiophen-2-ylmethyl)propenamide,

[0203] N-(pyridin-2-yl)-N-(thiophen-2-ylmethyl)-2-(p-tolyloxy)propenamide, N-ethyl-N-(thiophen-2-ylmethyl)-2-(p-tolyloxy)propenamide,

[0204] N-benzyl-N-phenyl-2-(p-tolyloxy)acetamide,

[0205] N-ethyl-3-(3-fluorophenyl)-N-(thiophen-2-ylmethyl)propenamide,

[0206] N-ethyl-N-(thiophen-2-ylmethyl)-3-m-tolylpropanamide,

[0207] N-phenyl-N-(thiophen-2-ylmethyl)benzofuran-2-carboxamide,

[0208] N-(2-ethylhexyl)-3-(4-hydroxyphenyl)propenamide,

[0209] N-ethyl-N-(thiophen-2-ylmethyl)benzofuran-2 -carboxamide,

[0210] 2-(4-cyanophenoxy)-N-ethyl-N-(thiophen-2-ylmethyl)acetamide,

[0211] N-(1-methyl-1 H-imidazol-2-yl)-N-(thiophen-2-ylmethyl)-2-(p-tolyloxy)acetamide,

[0212] 3-(3,5-difluorophenyl)-N-(2-ethylhexyl)propenamide,

[0213] N-ethyl-3-(4-methoxyphenyl)-N-(thiophen-2-ylmethyl)propenamide,

[0214] (R)-2-(3-chlorophenoxy)-N-(3-methylbutan-2-yl)acetamide,

[0215] N-ethyl-2-(2-fluorophenoxy)-N-(thiophen-2-ylmethyl)acetamide,

[0216] N-(2-ethylhexyl)-3-m-tolylpropanamide,

[0217] N-(2-ethylhexyl)-3-(3-fluorophenyl)propenamide,

[0218] 2-(4-(hydroxymethyl)phenoxy)-N-phenyl-N-(thiophen-2-ylmethyl)acetamide,

[0219] N-cyclohexyl-N-phenyl-2-(p-tolyloxy)acetamide,

[0220] N-(2-ethylhexyl)-3-phenylpropanamide,

[0221] 2-(6-methyl-4-oxo-4H-chromen-2-yloxy)-N-phenyl-N-(thiophen-2-ylmethyl)acetamide, N-ethyl-3-(4-oxo-3,4-dihydroquinazolin-2-yl)-N-(thiophen-2-ylmethyl)propenamide, 2-(4-hydroxyphenoxy)-N-phenyl-N-(thiophen-2-ylmethyl)acetamide,

[0222] 2-(4-cyanophenoxy)-N-phenyl-N-(thiophen-2-ylmethyl)acetamide,

[0223] N-(2-ethylhexyl)-3-(thiophen-2-yl)propenamide,

[0224] N-propyl-N-(thiophen-2-ylmethyl)-2-(p-tolyloxy)acetamide,

[0225] N-(pyridin-2-yl)-N-(thiophen-2-ylmethyl)-3-p-tolylpropanamide,

[0226] N-(2-ethylhexyl)-3-(3-methoxyphenyl)propenamide,

[0227] 2-(benzyloxy)-N-phenyl-N-(thiophen-2-ylmethyl)acetamide,

[0228] N-isopropyl-N-phenyl-2-(p-tolyloxy)acetamide,

[0229] N-phenyl-N-(pyridin-4-ylmethyl)-2-(p-tolyloxy)acetamide,

[0230] N-ethyl-2-methyl-N-(thiophen-2-ylmethyl)-2-(p-tolyloxy)propenamide,

[0231] 2-(2-hydroxy-4-methylphenoxy)-N-(1 H-pyrazol-4-yl)-N-(thiophen-2- ylmethyl)acetam ide,

[0232] (E)-N-ethyl-3-(4-methoxyphenyl)-N-(thiophen-2-ylmethyl)acrylamide,

[0233] (E)-N-ethyl-N-(furan-3-ylmethyl)-3-p-tolylacrylamide, (E)-N-ethyl-N-(thiophen-2-ylmethyl)-3-o-tolylacrylamide,

[0234] (E)-3-(benzo[d][1 ,3]dioxol-5-yl)-N-ethyl-N-(furan-3-ylmethyl)acrylamide, (E)-3-(2,3-dihydrobenzofuran-5-yl)-N-ethyl-N-(thiophen-2-ylmethyl)acrylamide, (E)-3-(2,3-dihydrobenzo[b][1 ,4]dioxin-6-yl)-N-ethyl-N-(thiophen-2- ylmethyl)acrylamide,

[0235] N-ethyl-5-methyl-N-(thiophen-2-ylmethyl)benzofuran-2 -carboxamide,

[0236] N-ethyl-N-(thiophen-2-ylmethyl)-3-p-tolylpropanamide,

[0237] (E)-N-ethyl-3-(4-fluorophenyl)-N-(thiophen-2-ylmethyl)acrylamide, (E)-3-(2,3-dihydro-1 H-inden-5-yl)-N-ethyl-N-(furan-3-ylmethyl)acrylamide, (E)-N-ethyl-3-(5-methylthiophen-2-yl)-N-(thiophen-2-ylmethyl)aciylamide, (E)-3-(benzo[d][1 ,3]dioxol-5-yl)-N-ethyl-N-(furan-2-ylmethyl)acrylamide, (E)-3-(2,3-dihydro-1 H-inden-5-yl)-N-ethyl-N-(thiophen-2-ylmethyl)acrylamide, N-ethyl-5-methoxy-N-(thiophen-2-ylmethyl)benzofuran-2 -carboxamide, (E)-N-ethyl-3-(3-hydroxy-4-methoxyphenyl)-N-(thiophen-2-ylmethyl)acrylamide, (E)-N-ethyl-N-(furan-2-ylmethyl)-3-p-tolylacrylamide, (E)-N-ethyl-3-(2-fluorophenyl)-N-(thiophen-2-ylmethyl)acrylamide,

[0238] (E)-N-ethyl-N-(thiophen-2-ylmethyl)-3-m-tolylacrylamide,

[0239] (E)-N-ethyl-3-(3-methoxyphenyl)-N-(thiophen-2-ylmethyl)acrylamide, (E)-3-(2,2-difluorobenzo[d][1 ,3]dioxol-5-yl)-N-ethyl-N-(thiophen-2- ylmethyl)acrylamide, (E)-N-ethyl-3-(3-fluorophenyl)-N-(thiophen-2-ylmethyl)acrylamide, (E)-N-ethyl-3-(5-methylfuran-2-yl)-N-(thiophen-2-ylmethyl)acrylamide, (E)-3-(4-cyanophenyl)-N-ethyl-N-(thiophen-2-ylmethyl)acrylamide, (E)-N-ethyl-3-(thiophen-2-yl)-N-(thiophen-2-ylmethyl)acrylamide, (E)-3-(2-cyanophenyl)-N-ethyl-N-(thiophen-2-ylmethyl)acrylamide, (E)-3-(2,3-dihydro-1 H-inden-5-yl)-N-ethyl-N-(furan-2-ylmethyl)acrylamide, 3-(2,3-dihydro-1 H-inden-5-yl)-N-ethyl-N-(thiophen-2-ylmethyl)propenamide, (E)-N-ethyl-N-(thiophen-2-ylmethyl)-3-(thiophen-3-yl)acrylamide, (E)-3-(3-cyanophenyl)-N-ethyl-N-(thiophen-2-ylmethyl)acrylamide, (E)-N-ethyl-3-(4-hydroxyphenyl)-N-(thiophen-2-ylmethyl)acrylamide, (E)-N-ethyl-3-(1-methyl-1 H-pyrrol-2-yl)-N-(thiophen-2-ylmethyl)acrylamide, (E)-N-ethyl-3-(1-methyl-1 H-pyrrol-2-yl)-N-(thiophen-2-ylmethyl)acrylamide,

[0240] (E)-N-ethyl-3-(2-methoxyphenyl)-N-(thiophen-2-ylmethyl)acrylamide, (E)-N-ethyl-3-(3-hydroxyphenyl)-N-(thiophen-2-ylmethyl)acrylamide, 2-(3-cyanophenoxy)-N-phenyl-N-(thiophen-2-ylmethyl)acetamide, 2-bromo-N-phenyl-N-(thiophen-2-ylmethyl)acetamide, N-ethyl-2-(2-hydroxy-5-methylphenoxy)-N-(thiophen-2-ylmethyl)acetamide, N-ethyl-2-(3-fluoro-4-methylphenoxy)-N-(thiophen-2-ylmethyl)acetamide, 2-(3-fluoro-4-methylphenoxy)-N-phenyl-N-(thiophen-2-ylmethyl)acetamide, 2-(4-fluoro-3-methylphenoxy)-N-phenyl-N-(thiophen-2-ylmethyl)acetamide, 2-(5-methylpyridin-2-yloxy)-N-phenyl-N-(thiophen-2-ylmethyl)acetamide, 2-(3-fluoro-4-methoxyphenoxy)-N-phenyl-N-(thiophen-2-ylmethyl)acetamide, 2-(6-methylpyridin-2-yloxy)-N-phenyl-N-(thiophen-2-ylmethyl)acetamide, 2-(6-methylpyridin-3-yloxy)-N-phenyl-N-(thiophen-2-ylmethyl)acetamide, N-phenyl-N-(thiophen-2-ylmethyl)-2-(4-(trifluoromethyl)phenoxy)acetamide, N-phenyl-N-(thiophen-2-ylmethyl)-2-(thiophen-2-yloxy)acetamide, 2-(4-allyl-2-methoxyphenoxy)-N-phenyl-N-(thiophen-2-ylmethyl)acetamide, or any combination thereof.

[0241] Other suitable cooling enhancing compound include, but are not limited to, (E / Z)-2- methyl-2-butenal, (E / Z)-2-isopropyl-5-methyl-2-hexenal, blumeatin, butin, eriodictyol, hesperetin, hesperidin, homoeriodictyol, isosakuranetin, naringenin, naringin, pinocembrin, poncirin, sakuranetin, sakuranin, sterubin, pinostrobin, aspalathin, naringin dihydrochalcone, hesperetin dihydrochalcone, hesperetin dihydrochalcone 4’-O-glucoside, neohesperedin dihydrochalcone, nothofagin, phloretin, methyl acetate, (+)-methyl(1 R)-cis-3-oxo-2-pentyl-1 -cyclopentaneacetate, n-(l -propylbutyl)- 1 ,3-benzodioxole-5-carboxamide, ferulic acid, a cyclohexanecarboxylic acid, a polymethoxy flavonoid, 3-(1 -((3,5-dimethylisoxazol-4-yl)methyl)-1 H-pyrazol-4-yl)-1 -(3- hydroxybenzyl)imidazolidine-2, 4-dione, or a mixture comprising (+-)-4-[(3,3-dimethyl- 2-oxiranyl)methoxy]-7H-furo[3,2-g]chromen-7-one, (+-)-4-(2,3-dihydroxy-3- methylbutoxy)-7H-furo[3,2-g]chromen-7-one, 5,7-dimethoxy-2H-chromen-2-one, and (+-)-9-[(3,3-dimethyl-2-oxiranyl)methoxy]-4-methoxy-7H-furo[3,2-g]chromen-7-one, or any combination thereof.

[0242] According to an embodiment, the cooling enhancing compound is chosen in the group consisting of (E / Z)-2-isopropyl-5-methyl-2-hexenal, naringenin, methyl acetate, and mixtures thereof. “(E / Z)-2-isopropyl-5-methyl-2-hexenal” and “methylisopropyl hexenal” can be used indifferently in the present invention. According to an embodiment, the cooling enhancing compound is a mixture of (E / Z)- 2-isopropyl-5-methyl-2-hexenal and naringenin.

[0243] According to an embodiment, the composition comprises the cooling enhancing compound in an amount comprised between 0.001 % and 0.5%, more preferably between 0.001 % and 0.2%, even more preferably between 0.001 % and 0.1 %, even more preferably between 0.005% and 0.1 % based on the total weight of the composition.

[0244] In an embodiment, the composition comprises the cooling enhancing compound in an amount of from 0.003% and 0.01 %, typically from 0.003% and 0.0065%, based on the total weight of the composition.

[0245] According to a particular embodiment, the composition comprises a cooling compound and a cooling enhancing compound. Typically, the ratio between the cooling enhancing compound and the cooling compound is above 1 / 1000, preferably between 1 / 100 and 1 / 10. In an embodiment, the ratio between the cooling enhancing compound and the cooling compound is from 1 / 100 to 1 / 20, typically 1 / 100 to 1 / 25.

[0246] According to an embodiment, the composition comprises of (E / Z)-2-isopropyl-5- methyl-2-hexenal and menthol. Preferably, the composition comprises menthol in an amount comprised between 0.01 % and 2%, more preferably between 0.1 % and 1 %, preferably between 0.2% and 0.5% based on the total weight of the composition. Preferably, the composition comprises (E / Z)-2-isopropyl-5-methyl-2-hexenal in an amount comprised between 0.001 % and 0.5%, more preferably between 0.001 % and 0.2%, even more preferably between 0.001 % and 0.1 %, even more preferably between 0.005% and 0.1 % based on the total weight of the composition.

[0247] In a certain embodiment, the composition comprises menthol in an amount from 0.05% to 0.5%, typically from 0.05% to 0.3%, more typically 0.15% and 0.3%, based on the total weight of the composition. Typically, the composition comprises (E / Z)-2- isopropyl-5-methyl-2-hexenal in an amount of from 0.003% and 0.01 %, typically from 0.003% and 0.0065%, based on the total weight of the composition. According to an embodiment, the composition comprises of (E / Z)-2-isopropyl-5- methyl-2-hexenal, butyl methoxydibenzoylmethane, preferably with menthol.

[0248] According to an embodiment, the composition comprises of (E / Z)-2-isopropyl-5- methyl-2-hexenal, n-hexyl 2-(4-diethylamino-2- hydroxybenzoyl)benzoate, preferably with menthol.

[0249] According to an embodiment, the composition comprises of (E / Z)-2-isopropyl-5- methyl-2-hexenal, bis-ethylhexyloxyphenol methoxyphenyl triazine, preferably with menthol.

[0250] Optional hydrophobic material

[0251] The hydrophobic material according to the invention can be “inert” material like solvents or active ingredients.

[0252] By “active ingredient”, it is meant a single compound or a combination of ingredients.

[0253] By “perfume oil”, it is meant a single perfuming compound or a mixture of several perfuming compounds.

[0254] By “hydrophobic material”, it is meant any hydrophobic material which forms a two- phase dispersion when mixed with water. The hydrophobic material is typically liquid at about 20°C.

[0255] According to an embodiment, the hydrophobic material is a hydrophobic active ingredient.

[0256] When the hydrophobic material is an active ingredient, it is preferably chosen from the group consisting of perfumes, perfume ingredients, nutraceuticals, cosmetics, pest control agents, biocide actives and mixtures thereof.

[0257] According to a particular embodiment, the hydrophobic material comprises a mixture of a perfume with another ingredient selected from the group consisting of nutraceuticals, cosmetics, pest control agents and biocide actives.

[0258] According to a particular embodiment, the hydrophobic material comprises a mixture of biocide actives with another ingredient selected from the group consisting of perfumes, nutraceuticals, cosmetics, pest control agents.

[0259] According to a particular embodiment, the hydrophobic material comprises a mixture of pest control agents with another ingredient selected from the group consisting of perfumes, nutraceuticals, cosmetics, biocide actives. According to a particular embodiment, the hydrophobic material comprises a perfume. According to a particular embodiment, the hydrophobic material consists of a perfume. According to a particular embodiment, the hydrophobic material consists of biocide actives.

[0260] According to a particular embodiment, the hydrophobic material consists of pest control agents.

[0261] By “perfume” (or also “perfume oil”) what is meant here is an ingredient or a composition that is a liquid at about 20°C. According to any one of the above embodiments said perfume oil can be a perfuming ingredient alone or a mixture of ingredients in the form of a perfuming composition. As a “perfuming ingredient” it is meant here a compound, which is used for the primary purpose of conferring or modulating an odor. In other words such an ingredient, to be considered as being a perfuming one, must be recognized by a person skilled in the art as being able to at least impart or modify in a positive or pleasant way the odor of a composition, and not just as having an odor. For the purpose of the present invention, perfume oil also includes a combination of perfuming ingredients with substances which together improve, enhance or modify the delivery of the perfuming ingredients, such as perfume precursors, modulators, emulsions or dispersions, as well as combinations which impart an additional benefit beyond that of modifying or imparting an odor, such as long-lastingness, blooming, malodor counteraction, antimicrobial effect, microbial stability, pest control.

[0262] The nature and type of the perfuming ingredients present in the oil phase do not warrant a more detailed description here, which in any case would not be exhaustive, the skilled person being able to select them on the basis of its general knowledge and according to intended use or application and the desired organoleptic effect. In general terms, these perfuming ingredients belong to chemical classes as varied as alcohols, aldehydes, ketones, esters, ethers, acetates, nitriles, terpenoids, nitrogenous or sulfurous heterocyclic compounds and essential oils (for example Thyme oil), and said perfuming co-ingredients can be of natural or synthetic origin. Many of these coingredients are in any case listed in reference texts such as the book by S. Arctander, Perfume and Flavor Chemicals, 1969, Montclair, New Jersey, USA, or its more recent versions, or in other works of a similar nature, as well as in the abundant patent literature in the field of perfumery. In particular one may cite perfuming ingredients which are commonly used in perfume formulations, such as:

[0263] - Aldehydic ingredients: decanal, dodecanal, 2-methyl-undecanal, 10- undecenal, octanal, nonanal and / or nonenal;

[0264] - Aromatic-herbal ingredients: eucalyptus oil, camphor, eucalyptol, 5- methyltricyclo[6.2.1 ,02’7]undecan-4-one, 1 -methoxy-3-hexanethiol, 2-ethyl-4,4- dimethyl-1 ,3-oxathiane, 2, 2, 7 / 8, 9 / 10-tetramethylspiro[5.5]undec-8-en-1 -one, menthol and / or alpha-pinene;

[0265] - Balsamic ingredients: coumarin, ethylvanillin and / or vanillin;

[0266] - Citrus ingredients: dihydromyrcenol, citral, orange oil, linalyl acetate, citronellyl nitrile, orange terpenes, limonene, 1 -p-menthen-8-yl acetate and / or 1 ,4(8)-p- menthadiene;

[0267] - Floral ingredients: methyl dihydrojasmonate, linalool, citronellol, phenylethanol,

[0268] 3-(4-tert-butylphenyl)-2-methylpropanal, hexylcinnamic aldehyde, benzyl acetate, benzyl salicylate, tetrahydro-2-isobutyl-4-methyl-4(2H)-pyranol, beta ionone, methyl 2-(methylamino)benzoate, (E)-3-methyl-4-(2,6,6-trimethyl-2- cyclohexen-1 -yl)-3-buten-2-one, (1 E)-1 -(2,6,6-trimethyl-2-cyclohexen-1 -yl)-1 - penten-3-one, 1 -(2, 6, 6-trimethy 1-1 ,3-cyclohexadien-1 -yl)-2-buten-1 -one, (2E)- 1 -(2,6,6-trimethyl-2-cyclohexen-1 -yl)-2-buten-1 -one, (2E)-1 -[2,6,6-trimethyl-3- cyclohexen-1 -yl]-2-buten-1 -one, (2E)-1 -(2, 6, 6-trim ethy 1-1 -cyclohexen-1 -yl)-2- buten-1 -one, 3-(3, 3 / 1 , 1 -dimethyl-5-indanyl)propanal, 2,5-dimethyl-2- indanmethanol, 2,6,6-trimethyl-3-cyclohexene-1 -carboxylate, 3-(4,4-dimethyl- 1 -cyclohexen-1 -yl)propanal, hexyl salicylate, 3,7-dimethyl-1 ,6-nonadien-3-ol, 3-(4-isopropylphenyl)-2-methylpropanal, verdyl acetate, geraniol, p-menth-1 - en-8-ol, 4-(1 ,1 -dimethylethyl)-1 -cyclohexyle acetate, 1 , 1 -dimethyl-2- phenylethyl acetate, 4-cyclohexyl-2-methyl-2-butanol, amyl salicylate , high cis methyl dihydrojasmonate, 3-methyl-5-phenyl-1 -pentanol, verdyl proprionate, geranyl acetate, tetrahydro linalool, cis-7-p-menthanol, propyl (S)-2-(1 ,1 - dimethylpropoxy)propanoate, 2-methoxynaphthalene, 2 , 2 ,2-trich loro-1 - phenylethyl acetate, 4 / 3-(4-hydroxy-4-methylpentyl)-3-cyclohexene-1 - carbaldehyde, amylcinnamic aldehyde, 8-decen-5-olide, 4-phenyl-2-butanone, isononyle acetate, 4-(1 , 1 -dimethylethyl)-1 -cyclohexyl acetate, verdyl isobutyrate and / or mixture of methylionones isomers; - Fruity ingredients: gamma-undecalactone, 2,2,5-trimethyl-5- pentylcyclopentanone, 2-methyl-4-propyl-1 ,3-oxathiane, 4-decanolide, ethyl 2- methyl-pentanoate, hexyl acetate, ethyl 2-methylbutanoate, gammanonalactone, allyl heptanoate, 2-phenoxyethyl isobutyrate, ethyl 2-methyl-1 ,3- dioxolane-2-acetate, diethyl 1 ,4-cyclohexanedicarboxylate, 3-methyl-2-hexen- 1 -yl acetate, 1 -[3,3-dimethylcyclohexyl]ethyl [3-ethyl-2-oxiranyl]acetate and / or diethyl 1 ,4-cyclohexane dicarboxylate;

[0269] - Green ingredients: 2-methyl-3-hexanone (E)-oxime, 2,4-dimethyl-3- cyclohexene-1 -carbaldehyde, 2-tert-butyl-1 -cyclohexyl acetate, styrallyl acetate, allyl (2-methylbutoxy)acetate, 4-methyl-3-decen-5-ol, diphenyl ether, (Z)-3-hexen-1 -ol and / or 1 -(5,5-dimethyl-1 -cyclohexen-1 -yl)-4-penten-1 -one;

[0270] - Musk ingredients: 1 ,4-dioxa-5, 17-cycloheptadecanedione, (Z)-4- cyclopentadecen-1 -one, 3-methylcyclopentadecanone, 1 -oxa-12- cyclohexadecen-2-one, 1 -oxa-13-cyclohexadecen-2-one, (9Z)-9- cycloheptadecen-1 -one, 2-{(1 S)-1 -[(1 R)-3,3-dimethylcyclohexyl]ethoxy}-2- oxoethyl propionate, 3-methyl-5-cyclopentadecen-1 -one, 4, 6, 6, 7,8,8- hexamethyl-1 ,3,4,6,7,8-hexahydrocyclopenta[g]isochromene, (1 S, 1'R)-2-[1 - (3',3'-dimethyl-T-cyclohexyl)ethoxy]-2-methylpropyl propanoate, oxacyclohexadecan-2-one and / or (1 S,1 'R)-[1 -(3',3'-dimethyl-T- cyclohexyl)ethoxycarbonyl]methyl propanoate;

[0271] - Woody ingredients: 1 -[(1 RS,6SR)-2,2,6-trimethylcyclohexyl]-3-hexanol, 3,3- dimethyl-5-[(1 R)-2,2,3-trimethyl-3-cyclopenten-1 -yl]-4-penten-2-ol, 3,4'- dimethylspiro[oxirane-2,9'-tricyclo[6.2.1 ,02’7]undec[4]ene, (1 - ethoxyethoxy)cyclododecane, 2,2,9, 11 -tetramethylspiro[5.5]undec-8-en-1 -yl acetate, 1 -(octahydro-2,3,8,8-tetramethyl-2-naphtalenyl)-1 -ethanone, patchouli oil, terpenes fractions of patchouli oil, Clearwood®, (1 'R, E)-2-ethyl-4-(2',2',3'- trimethyl-3'-cyclopenten-1 '-yl)-2-buten-1 -ol, 2-ethyl-4-(2,2,3-trimethyl-3- cyclopenten-1 -yl)-2-buten-1 -ol, methyl cedryl ketone, 5-(2,2,3-trimethyl-3- cyclopentenyl)-3-methylpentan-2-ol, 1 -(2,3,8,8-tetramethyl-1 ,2,3,4,6,7,8,8a- octahydronaphthalen-2-yl)ethan-1 -one and / or isobornyl acetate;

[0272] - Other ingredients (e.g. amber, powdery spicy or watery): dodecahydroSa, 6,6, 9a-tetramethyl-naphtho[2,1 -b]furan and any of its stereoisomers, heliotropin, anisic aldehyde, eugenol, cinnamic aldehyde, clove oil, 3-(1 ,3- benzodioxol-5-yl)-2-methylpropanal, 7-methyl-2H-1 ,5-benzodioxepin-3(4H)- one, 2 , 5, 5-trimethyl-1 ,2,3,4,4a,5,6,7-octahydro-2-naphthalenol, 1 -phenylvinyl acetate, 6-methyl-7-oxa-1 -thia-4-azaspiro[4.4]nonane and / or 3-(3-isopropyl-1 - phenyl)butanal.

[0273] It is also understood that said ingredients may also be compounds known to release in a controlled manner various types of perfuming compounds also known as properfume or profragrance. Non-limiting examples of suitable properfumes may include 4-(dodecylthio)-4-(2,6,6-trimethyl-2-cyclohexen-1 -yl)-2-butanone, 4- (dodecylthio)-4-(2,6,6-trimethyl-1 -cyclohexen-1 -yl)-2-butanone, 3-(dodecylthio)-1 - (2,6,6-trimethyl-3-cyclohexen-1 -y l)-1 -butanone, 2-(dodecylthio)octan-4-one, 2- phenylethyl oxo(phenyl)acetate, 3,7-dimethylocta-2,6-dien-1 -yl oxo(phenyl)acetate, (Z)-hex-3-en-1 -yl oxo(phenyl)acetate, 3,7-dimethyl-2,6-octadien-1 -yl hexadecanoate, bis(3,7-dimethylocta-2,6-dien-1 -yl) succinate, (2-((2-methylundec-1 -en-1 - yl)oxy)ethyl)benzene, 1 -methoxy-4-(3-methyl-4-phenethoxybut-3-en-1 -yl)benzene, (3-methyl-4-phenethoxybut-3-en-1 -yl)benzene, 1 -(((Z)-hex-3-en-1 -yl)oxy)-2- methylundec-1 -ene, (2-((2-methylundec-1 -en-1 -yl)oxy)ethoxy)benzene, 2-methyl-1 - (octan-3-yloxy)undec-1 -ene, 1 -methoxy-4-(1 -phenethoxyprop-1 -en-2-yl)benzene, 1 - methyl-4-(1 -phenethoxyprop-1 -en-2-yl)benzene, 2-(1 -phenethoxyprop-1 -en-2- yl)naphthalene, (2-phenethoxyvinyl)benzene, 2-(1 -((3,7-dimethyloct-6-en-1 - yl)oxy)prop-1 -en-2-yl)naphthalene, (2-((2- pentylcyclopentylidene)methoxy)ethyl)benzene, 4-allyl-2-methoxy-1 -((2-methoxy-2- phenylvinyl)oxy)benzene, (2-((2-heptylcyclopentylidene)methoxy)ethyl)benzene, 1 - isopropyl-4-methyl-2-((2-pentylcyclopentylidene)methoxy)benzene, 2-methoxy-1 -((2- pentylcyclopentylidene)methoxy)-4-propylbenzene, 3-methoxy-4-((2-m ethoxy-2 - phenylvinyl)oxy)benzaldehyde, 4-((2-(hexyloxy)-2-phenylvinyl)oxy)-3- methoxybenzaldehyde or a mixture thereof.

[0274] The perfuming ingredients may be dissolved in a solvent of current use in the perfume industry. The solvent is preferably not an alcohol. Examples of such solvents are diethyl phthalate, isopropyl myristate, Abalyn® (rosin resins, available from Eastman), benzyl benzoate, ethyl citrate, triethyl citrate, limonene or other terpenes, or isoparaffins. Preferably, the solvent is very hydrophobic and highly sterically hindered, like for example Abalyn® or benzyl benzoate. Preferably the perfume comprises less than 30% of solvent. More preferably the perfume comprises less than 20% and even more preferably less than 10% of solvent, all these percentages being defined by weight relative to the total weight of the perfume. Most preferably, the perfume is essentially free of solvent.

[0275] According to an embodiment, the oil phase (or the oil-based core) comprises 25- 100wt% of a perfume oil comprising at least 15wt% of high impact perfume raw materials having a Log T<-4.

[0276] The nature of high impact perfume raw materials having a Log T<-4 are described in WO201 8115250, the content of which are included by reference.

[0277] “High impact perfume raw materials” should be understood as perfume raw materials having a LogT<-4. The odor threshold concentration of a chemical compound is determined in part by its shape, polarity, partial charges and molecular mass. For convenience, the odor threshold concentration is presented as the common logarithm of the threshold concentration, i.e., Log [Threshold] (“LogT”).

[0278] The odor threshold concentration of a perfuming compound is determined by using a gas chromatograph (“GC”). Specifically, the gas chromatograph is calibrated to determine the exact volume of the perfume oil ingredient injected by the syringe, the precise split ratio, and the hydrocarbon response using a hydrocarbon standard of known concentration and chain-length distribution. The air flow rate is accurately measured and, assuming the duration of a human inhalation to last 12 seconds, the sampled volume is calculated. Since the precise concentration at the detector at any point in time is known, the mass per volume inhaled is known and hence the concentration of the perfuming compound. To determine the threshold concentration, solutions are delivered to the sniff port at the back-calculated concentration. A panelist sniffs the GC effluent and identifies the retention time when odor is noticed. The average across all panelists determines the odor threshold concentration of the perfuming compound. The determination of odor threshold is described in more detail in C. Vuilleumier et al., Multidimensional Visualization of Physical and Perceptual Data Leading to a Creative Approach in Fragrance Development, Perfume & Flavorist, Vol. 33, September, 2008, pages 54-61. According to an embodiment, the hydrophobic material is chosen in the group consisting of limonene, citral, linalool, alpha-isomethylionone, geraniol, citronellol, 2- isobutyl-4-hydroxy-4-methyltetrahydropyran, 2-tert-pentylcyclohexyl acetate, 3- methyl-5-phenyl-1 -pentanol, 7-acetyl-1 ,1 ,3,4,4, 6-hexamethyltetralin, adipic diester, cinnamal, amyl salicylate, alpha-amylcinnamaldehyde, alpha-methylionone, butylphenylmethylpropional, cinnamal, amylcinnamyl alcohol, anise alcohol, benzoin, benzyl alcohol, benzyl benzoate, benzyl cinnamate, benzyl salicylate, bergamot oil, bitter orange oil, butylphenylmethylpropional, cardamom oil, cedrol, cinnamal, cinnamyl alcohol, citronellyl methylcrotonate, citrus oil, coumarin, diethyl succinate, ethyllinalool, eugenol, Evernia furfuracea extract, Evernia prunastri extract, farnesol, guaiacwood oil, hexylcinnamal, hexyl salicylate, hydroxycitronellal, lavender oil, lemon oil, linalyl acetate, mandarin oil, methyl hexadecan, nutmeg oil, rosemary oil, sweet orange oil, terpineol, tonkabean oil, triethyl citrate, vanillin.

[0279] In a particular embodiment, the perfume oil, has a biodegradability of at least 40 %, preferably at least 60 %, preferably at least 65%, 70%, 75%, 80%, 85%, 90%, 95% or 98% within 60 days according to OECD301 F.

[0280] OECD301 F is a standard test method on the biodegradability from the Organization of Economic Co-operation and Development.

[0281] According to an embodiment, the composition comprises the perfume oil in an amount comprised between 0.01 % and 10%, preferably between 0.05% and 2% by weight based on the total weight of the composition.

[0282] According to a particular embodiment, the hydrophobic material is free of any active ingredient (such as perfume). According to this particular embodiment, it comprises, preferably consists of hydrophobic solvents, preferably chosen in the group consisting of isopropyl myristate, tryglycerides (e.g. Neobee® MCT oil, vegetable oils), D- limonene, silicone oil, mineral oil, and mixtures thereof with optionally hydrophilic solvents preferably chosen in the group consisting of 1 ,4-butanediol, benzyl alcohol, triethyl citrate, triacetin, benzyl acetate, ethyl acetate, propylene glycol (1 ,2- propanediol), 1 ,3-propanediol, dipropylene glycol, glycerol, glycol ethers and mixtures thereof . The term "biocide" refers to a chemical substance capable of killing living organisms (e.g. microorganisms) or reducing or preventing their growth and / or accumulation. Biocides are commonly used in medicine, agriculture, forestry, and in industry where they prevent the fouling of, for example, water, agricultural products including seed, and oil pipelines. A biocide can be a pesticide, including a fungicide, herbicide, insecticide, algicide, molluscicide, miticide and rodenticide; and / or an antimicrobial such as a germicide, antibiotic, antibacterial, antiviral, antifungal, antiprotozoal and / or antiparasite.

[0283] As used herein, a "pest control agent" indicates a substance that serves to repel or attract pests, to decrease, inhibit or promote their growth, development or their activity. Pests refer to any living organism, whether animal, plant or fungus, which is invasive or troublesome to plants or animals, pests include insects notably arthropods, mites, spiders, fungi, weeds, bacteria and other microorganisms.

[0284] Compositions

[0285] As the compositions according to the invention are intended for topical application, it is well understood that they comprise a physiologically acceptable medium, i.e. a medium compatible with keratinous substances, such as the skin, mucous membranes, and keratinous fibres. In particular, the physiologically acceptable medium is a cosmetically acceptable carrier.

[0286] The term ‘cosmetically acceptable carrier’ as used herein refers to all carriers and / or excipients and / or diluents conventionally used in topical cosmetic compositions such as in particular in skin care preparations.

[0287] The exact amount of carrier will depend upon the actual level of the UV filters and any other optional ingredients that one of ordinary skill in the art would classify as distinct from the carrier (e.g., other active ingredients).

[0288] In an advantageous embodiment, the compositions according to the present invention comprise from 50% to 99%, preferably from 60% to 98%, more preferably from 70% to 98%, such as in particular from 80% to 95% of a carrier, based on the total weight of the composition.

[0289] In a particular advantageous embodiment, the carrier in all embodiments of the present invention consists furthermore of at least 30 wt. %, more preferably of at least 40 wt.-%, most preferably of at least 45 wt.-% of water, such as in particular of 50 to 90 wt.-%, from 50 to 80 wt.-%, from 50 to 79 wt.-% or from 50 to 60 wt.-% of water.

[0290] In particular, the compositions according to the present invention are cosmetic or pharmaceutical compositions, preferably cosmetic (non-therapeutic) compositions.

[0291] In one embodiment, the compositions according to the present invention are applied to mammalian keratinous tissue such as in particular to human skin or the human scalp and hair.

[0292] The term “cosmetic composition” as used in the present application refers to cosmetic compositions as defined under the heading “Kosmetika” in Rdmpp Lexikon Chemie, 10thedition 1997, Georg Thieme Verlag Stuttgart, New York as well as to cosmetic compositions as disclosed in A. Domsch, “Cosmetic Compositions”, Verlag fur chemische Industrie (ed. H. Ziolkowsky), 4thedition, 1992.

[0293] Preferred compositions according to the invention are skin care preparations, decorative preparations, and functional preparations.

[0294] Examples of skin care preparations are, in particular, light protective preparations, antiageing preparations, preparations for the treatment of photo-ageing, body oils, body lotions, body gels, treatment creams, skin protection ointments, skin powders, moisturizing gels, moisturizing sprays, face and / or body moisturizers, skin-tanning preparations (i.e. compositions for the artificial / sunless tanning and / or browning of human skin), for example self-tanning creams as well as skin lightening preparations.

[0295] Examples of decorative preparations are in particular lipsticks, eye shadows, mascaras, dry and moist make-up formulations, rouges and / or powders. Examples of functional preparations are cosmetic or pharmaceutical compositions containing active ingredients such as hormone preparations, vitamin preparations, vegetable extract preparations, anti-ageing preparations, and / or antimicrobial (antibacterial or antifungal) preparations without being limited thereto.

[0296] In a particular embodiment, the compositions according to the invention are light- protective preparations (sun care products, sunscreens), such as sun protection milks, sun protection lotions, sun protection creams, sun protection oils, sun blocks or day care creams with a SPF. Of particular interest are sun protection creams, sun protection lotions and sun protection milks.

[0297] Additional components

[0298] The compositions of the invention (including the carrier) may comprise conventional adjuvants and additives, such as preservatives / antioxidants, fatty substances / oils, organic solvents, silicones, thickeners, softeners, emulsifiers, antifoaming agents, aesthetic components such as fragrances, surfactants, fillers, anionic, cationic, nonionic or amphoteric polymers or mixtures thereof, propellants, acidifying or basifying agents, dyes, colorings / colorants, abrasives, absorbents, chelating agents and / or sequestering agents, essential oils, skin sensates, astringents, pigments or any other ingredients usually formulated into such compositions.

[0299] In accordance with the present invention, the compositions according to the invention may comprise further ingredients such as ingredients for skin lightening; tanning prevention; treatment of hyperpigmentation; preventing or reducing acne, wrinkles, lines, atrophy and / or inflammation; chelators and / or sequestrants; anti-cellulites and slimming (e.g. phytanic acid), firming, moisturizing and energizing, self-tanning, soothing agents, as well as agents to improve elasticity and skin barrier and carriers and / or excipients or diluents conventionally used in compositions.

[0300] If nothing else is stated, the excipients, additives, diluents, etc. mentioned in the following are suitable for compositions according to the present invention. The necessary amounts of the cosmetic and dermatological adjuvants and additives can, based on the desired product, easily be determined by the skilled person. The additional ingredients can either be added to the oily phase, the aqueous phase or separately as deemed appropriate. The mode of addition can easily be adapted by a person skilled in the art.

[0301] Examples of cosmetic excipients, diluents, adjuvants, additives as well as active ingredients commonly used in the skin care industry which are suitable for use in the cosmetic compositions of the present invention are for example described in the International Cosmetic Ingredient Dictionary & Handbook by Personal Care Product Council, without being limited thereto.

[0302] The cosmetically active ingredients useful herein can in some instances provide more than one benefit or operate via more than one mode of action.

[0303] Of course, one skilled in this art will take care to select the above mentioned optional additional ingredients, adjuvants, diluents and additives and / or their amounts such that the advantageous properties intrinsically associated with the combination in accordance with the invention are not, or not substantially, detrimentally affected by the envisaged addition or additions.

[0304] Preferred compositions in all embodiments of the present invention are emulsions containing an oily phase and an aqueous phase such as in particular an O / W, W / O, Si / W, W / Si, O / W / O, W / O / W multiple or a pickering emulsions. The amount of the oily phase (i.e. the phase containing all oils and fats) present in such emulsions is preferably at least 10 wt.-%, such as in the range from 10 to 60 wt.-%, preferably in the range from 15 to 50 wt.-%, most preferably in the range from 15 to 45 wt.-%, based on the total weight of the composition.

[0305] According to one even more preferred embodiment, the compositions according to the present invention as outlined herein are O / W emulsions comprising an oily phase dispersed in an aqueous phase in the presence of an O / W emulsifier. The preparation of such O / W emulsions is well known to a person skilled in the art and illustrated in the examples. According to an embodiment, the emulsion is a microemulsion.

[0306] In one advantageous embodiment, the O / W emulsifier is a phosphate ester emulsifier. Among the preferred phosphate ester emulsifier are C8-10 alkyl ethyl phosphate, CO- 15 alkyl phosphate, C20-22 alkyl phosphate, ceteareth-2 phosphate, ceteareth-5 phosphate, ceteth-8 phosphate, ceteth-10 phosphate, cetyl phosphate, C6-10 pareth- 4 phosphate, C12-15 pareth-2 phosphate, C12-15 pareth-3 phosphate, DEA- ceteareth-2 phosphate, DEA-cetyl phosphate, DEA-oleth-3 phosphate, potassium cetyl phosphate, deceth-4 phosphate, deceth-6 phosphate and tri laureth-4 phosphate. Particular preferred phosphate ester emulsifiers in all embodiments of the present invention are C8-C25 alkyl phosphates, such as in particular C20-22 alkyl phosphates and cetyl phosphates, and in particular the respective potassium salts thereof. A particular preferred phosphate ester emulsifier according to the invention is potassium cetyl phosphate e.g. commercially available as Amphisol® K at DSM Nutritional Products Ltd Kaiseraugst.

[0307] Further suitable O / W emulsifiers according to the present invention encompass PEG 30 Dipolyhydroxystearate, PEG-4 Dilaurate, PEG-8 Dioleate, PEG-40 Sorbitan Peroleate, PEG-7 Glyceryl Cocoate, PEG-20 Almond Glycerides, PEG-25 Hydrogenated Castor Oil, Glyceryl Stearate (and) PEG-100 Stearate , PEG-7 Olivate, PEG-8 Oleate, PEG-8 Laurate, PEG-60 Almond Glycerides, PEG-20 Methyl Glucose Sesquistearate, PEG-40 Stearate, PEG-100 Stearate, PEG-80 Sorbitan Laurate, Steareth-2, Steareth-12, Oleth-2, Ceteth-2, Laureth-4, Oleth-10, Oleth-10 / Polyoxyl 10 Oleyl Ether, Ceteth-10, lsosteareth-20, Ceteareth-20, Oleth-20, Steareth-20, Steareth- 21 , Ceteth-20, lsoceteth-20, Laureth-23, Steareth-100, glycerylstearatcitrate, glycerylstearate (self-emulsifying), stearic acid, salts of stearic acid, polyglyceryl-3- methylglycosedistearate. Further suitable emulsifiers are sorbitan oleate, sorbitan sesquioleate, sorbitan isostearate, sorbitan trioleate, Lauryl Glucoside, Decyl Glucoside, Sodium Stearoyl Glutamate, Sucrose Polystearate and Hydrated Polyisobuten. Furthermore, one or more synthetic polymers may be used as an emulsifier. For example, PVP eicosene copolymer, acrylates / C 10-30 alkyl acrylate crosspolymer, acrylates / steareth-20 methacrylate copolymer, PEG-22 / dodecyl glycol copolymer, PEG-45 / dodecyl glycol copolymer, and mixtures thereof. Further suitable are commercially available polymeric emulsifiers such as hydrophobically modified polyacrylic acid such as Acrylates / C 10-30 Alkyl Acrylate Crosspolymers which are commercially available under the tradename Pemulen® TR- 1 and TR-2 by Lubrizol.

[0308] Another class of particularly suitable emulsifiers are polyglycerol esters or diesters of fatty acids also called polyglyceryl ester / diester (i.e. a polymer in which fatty acid(s) is / are bound by esterification with polyglycerine), such as e.g. commercially available at Evonik as Isolan GPS [INCI Name Polyglyceryl-4 Diisostearate / Polyhydroxystearate / Sebacate (i.e. diester of a mixture of isostearic, polyhydroxystearic and sebacic acids with Polyglycerin-4)] or Dehymuls PGPH available at BASF (INCI Polyglyceryl-2 Dipolyhydroxystearate).

[0309] Particularly advantageous O / W emulsifiers according to the present invention are one or more of Polyglyceryl-3 Methylglucose Distearate, Lauryl Glucoside (and) Polyglyceryl-2 Dipolyhydroxystearate, Glyceryl Sterate Citrate, Sodium Cetearyl Sulfate, Cetearyl Glucoside; Polyglyceryl-6 Stearate (and) Polyglyceryl-6 Behenate, Cetearyl Olivate (and) Sorbitan Olivate, Arachidyl Alcohol (and) Behenyl Alcohol (and) Arachidyl Glucosides, Cetearyl Alcohol (and) Coco-Glucoside, Coco-Glucoside (and) Coconut Alcohol, PEG-100 Stearate (and) Glyceryl Stearate, Sodium Stearoyl Glutamate, Steareth-20, Steareth-21 , Steareth-25, Steareth-2, Ceteareth-25 and Ceteareth-6 (all listed by their INCI names).

[0310] In one embodiment it is particularly preferred in accordance with the invention if the composition comprises a C8-C25 alkyl phosphate, preferably a C20-22 alkyl phosphate and / or a cetyl phosphate, most preferably a cetyl phosphate such as in particular potassium cetyl phosphate as emulsifier or at least as a co-emulsifier.

[0311] The at least one O / W respectively Si / W emulsifier is preferably used in an amount of 0.5 to 10 wt. % such as in particular in the range of 0.5 to 5 wt.-% such as most in particular in the range of 0.5 to 4 wt.-% or in the range of 0.5 to 3 wt.-%, based on the total weight of the composition. If the phosphate ester emulsifier with all the definitions and preferences as given herein is used as a co-emulsifier, the amount is preferably selected in the range of 0.1 to 1 wt. % such as in particular in the range of 0.25 to 0.75 wt.-% such as most in particular in the range of 0.3 to 0.7 wt.-% or in the range of 0.4 to 0.6 wt.-%, based on the total weight of the composition.

[0312] Suitable W / O- or W / Si-emulsifiers according to the present invention are polyglyceryl- 2-dipolyhydroxystearat, PEG-30 dipolyhydroxystearate, cetyl dimethicone copolyol, polyglyceryl-3 diisostearate polyglycerol esters of oleic / isostearic acid, polyglyceryl-6 hexaricinolate, polyglyceryl-4-oleate, oleate / PEG-8 propylene glycol cocoate, magnesium stearate, sodium stearate, potassium laurate, potassium ricinoleate, sodium cocoate, sodium tallowate, potassium castorate, sodium oleate, and mixtures thereof. Further suitable W / Si-emulsifiers are Lauryl Polyglyceryl-3 Polydimethylsiloxyethyl Dimethicone and / or PEG-9 Polydimethylsiloxyethyl Dimethicone and / or Cetyl PEG / PPG-10 / 1 Dimethicone and / or PEG-12 Dimethicone Crosspolymer and / or PEG / PPG-18 / 18 Dimethicone. The at least one W / O emulsifier is preferably used in an amount of about 0.001 to 10 wt.-%, more preferably in an amount of 0.2 to 7 wt.-% with respect to the total weigh of the composition.

[0313] The compositions according to the present invention can furthermore advantageously contain at least one co-surfactant such as e.g. selected from the group of mono- and diglycerides and / or fatty alcohols. The co-surfactant is generally used in an amount selected in the range of 0.1 to 10 wt.-%, such as in particular in the range of 0.5 to 7 wt.-%, such as most in particular in the range of 1 to 5 wt.-%, based on the total weight of the composition. Particular suitable co-surfactants are selected from the list of alkyl alcohols such as cetyl alcohol (Lord C16, Lanette 16), cetearyl alcohol (Lanette O), stearyl alcohol (Lanette 18), behenyl alcohol (Lanette 22), polyhydroxystearic acid, glyceryl stearate, glyceryl myristate (Estol 3650), hydrogenated coco-glycerides (Lipocire Na10) as well as mixtures thereof.

[0314] Advantageous embodiments of the composition of the present invention also include those wherein the composition comprises one or more oils selected from butylene glycol dicaprylate / dicaprate, phenethyl benzoate, C12-C15 alkyl benzoate, dibutyl adipate, diisopropyl sebacate, dicaprylyl carbonate, isopropyl palmitate, Isopropyl myristate, coco-caprylate / caprate, butyloctyl salicylate, phenoxyethyl caprylate, isoamyl laurate, diisopropyl adipate di-Ci2-i3 alkyl tartrates, diethylhexyl syringylidene malonates, hydrogenated castor oil dimerates, triheptanoin, C12-13 alkyl lactates, C16- 17 alkyl benzoates, propylheptyl caprylates, capryl ic / capric triglycerides, diethylhexyl 2,6-naphthalates, octyldodecanol, ethylhexyl cocoates, and phenethyl alcohol. Preferably, the composition according to the present invention comprises as oil(s) dibutyl adipate, phenylethyl benzoate, C12-C15 alkylbenzoate, diisopropyl sebacate, palmitate, isoproyl myristate, diisopropyl adipate, coco-caprylate / caprate, dicaprylyl carbonate, capric / caprylic triglyceride as well as mixtures thereof.

[0315] In a still further advantageous aspect of the invention, the compositions of the present invention further comprise a preservative and / or a preservative booster, preferably selected from the group consisting of ethanol, phenoxyethanol, sodium benzoate, potassium sorbate, phenethyl alcohol, hydroxyacetophenone, ethylhexylglycerin, hexylglycerin, glyceryl caprylate, 1 ,3-propanediol, 1 ,2-pentanediol, 1 ,2-hexanediol,

[0316] 1 .2-octanediol (caprylyl glycol), 1 ,2-decanediol and 2-methyl-1 ,3-propanediol as well as mixtures thereof, most preferably selected from the group of phenoxyethanol and ethylhexyl glycerine as well as mixtures thereof. When present, the preservative respectively the preservative booster is preferably used in an amount of 0.01 to 5 wt. %, more preferably in an amount of 0.05 to 4 wt.-%, most preferably in an amount of 0.1 to 3.0 wt.-%, based on the total weight of the composition.

[0317] It is advantageous in accordance with the invention if the preparation comprises one or more alkanediols from the group 1 ,3-propanediol, 1 ,2-pentanediol, 1 ,2-hexanediol,

[0318] 1 .2-octanediol, 1 ,2-decanediol and 2-methyl-1 ,3-propanediol. When present, the one or more alkanediols is preferably used in an amount of 0.1 to 7 wt. %, more preferably in an amount of 0.5 to 7 wt.-%, most preferably in an amount of 1 .0 to 5.0 wt.-%, based on the total weight of the composition.

[0319] In another advantageous aspect, the compositions according to the present invention are free of any parabens, benzethonium chloride, piroctone olamine, lauroyl arginate, methylisothiazolinone, chloromethylisothiazolinone, bronopol, benzalkonium chloride, formaldehyde releasing compounds, salicylic acid, triclosan, DMDM hydantoin, chlorphenesin and IPBC (lodopropinylbutyl carbamate). The compositions according to the invention may further contain one or more emollients which soothe and soften the skin. As an example, the emollient may be silicone (dimethicone, cyclomethicone), vegetable oils (grape seed, sesame seed, jojoba, etc.), butters (cocoa butter, shea butter), and petrolatum derivatives (petroleum jelly, mineral oil).

[0320] The composition of the invention may advantageously comprise moisturizers. Moisturizers are compounds or mixtures of compounds which give cosmetic compositions the quality, after application to or distribution on the skin surface, of reducing the loss of moisture of the stratum corneum (also called transepidermal water loss (TEWL)) and / or of positively influencing the hydration of the stratum corneum.

[0321] Non-limiting examples of advantageous moisturizers for use in the present invention include glycerol, lactic acid and / or lactates, especially sodium lactate, butylene glycol, propylene glycol, 1 ,3-propanediol, biosaccharide gum-1 , Glycine soya, ethylhexyloxyglycerol, pyrrolidonecarboxylic acid, and urea. Of further advantage, in particular, is the use of polymeric moisturizers from the group of the polysaccharides which are water-soluble and / or swellable in water and / or gellable with the aid of water. Especially advantageous, for example, are hyaluronic acid, chitosan and / or a fucose- rich polysaccharide which is registered in Chemical Abstracts under the registry number 178463-23-5 and is available, for example, under the Fucogel®1000 name from the company SOLABIA S.A. Moisturizers may also be used advantageously as active antiwrinkle ingredients for protection from changes to the skin of the kind occurring in skin aging, for example.

[0322] Particularly advantageous moisturizers to be used in the compositions according to the present invention are glycerin, sodium hyaluronate, saccharide isomerate and / or 1 ,3-propanediol, more preferably in a total amount selected in the range of 0.1 to 5 wt.-%, more preferably in the range from to 0.1 to 3 wt.-%, even more preferably in the range of 0.5 to 3 wt.-%, based on the total weight of the composition.

[0323] The cosmetic compositions of the invention may further comprise advantageously, although not mandatorily, fillers which have the effect, for example, of further improving the sensorial and cosmetic properties of the formulations and evoking or intensifying a velvety or silky skin sensation, for example. Advantageous fillers in the sense of the present invention are starch and starch derivatives (such as tapioca starch, distarch phosphate, aluminum or sodium starch octenylsuccinate, and the like, for example), Valvance pigments which have neither primarily UV filter effect nor coloring effect (such as Valvance Touch 210 or 250 for example) and / or Aerosils® (CAS No. 7631 - 86-9) and / or talc and / or polyethylene, nylon, and silica dimethyl silylate.

[0324] The water phase of the compositions of the invention may advantageously comprise customary cosmetic auxiliaries, such as, for example, alcohols, particularly those of low C number, preferably ethanol and / or isopropanol, or polyols of low C number, and also ethers thereof, preferably propylene glycol, glycerol, electrolytes, self-tanning agents, and also, in particular, one or more thickeners, which may be advantageously selected from the group of silicon dioxide, aluminum silicates, polysaccharides and / or derivatives thereof, e.g., hyaluronic acid, xanthan gum, hydroxypropylmethylcellulose, particularly advantageously from the group of polyacrylates, preferably a polyacrylate from the group referred to as Carbopols, examples being carbopols of types 980, 981 , 1382, 2984, and 5984, in each case individually or in combination. Further thickeners advantageous in accordance with the invention are those having the INCI designation Acrylates / C 10-30 Alkyl Acrylate Crosspolymer (e.g., Pemulen TR 1 , Pemulen TR 2, Carbopol 1328 from Lubrizol) and also Aristoflex AVC (INCI: Ammonium Acryloyldimethyltaurate / VP Copolymer) as well as Simugel NS (INCI: Hydroxyethyl Acrylate / Sodium Acryloyldimethyl Taurate Copolymer & Squalane & Polysorbate 60). Further suitable thickeners in all embodiments of the present invention are biopolymers like Microcrystalline Cellulose, Cellulose, Cellulose gum, Sphingomonas ferment extract.

[0325] It is further preferred in accordance with the invention if the composition comprises a thickener. Suitable thickeners to be used according to the present invention encompass xanthan gum, microcrystalline cellulose, cellulose, cellulose gum, crosslinked acrylate / C10-C30 alkyl acrylate polymer, hydroxyethyl acrylate / sodium acryloyldimethyl taurate copolymer, and / or vinylpyrrolidone / hexadecane copolymer, preferably xanthan gum and / or cellulose based ingredient, most preferably xanthan gum. The amount of xanthan gum, if present is preferably selected in the range of 0.1 to 1 wt.-%, more preferably in the range of 0.15 to 0.75 wt.-%, most preferably in the range of 0.2 to 0.4 wt.-%, based on the total weight of the composition.

[0326] The oil phase of the compositions of the invention may advantageously also comprise customary cosmetic auxiliaries, such as, for example, thickeners for the oil phase such as Dextrin Palmitate (Rheopearl KL2, Chiba Flour Milling), Dextrin Palmitate and CI S- 19 Alkane (TILAMAR Fits, DSM), Polyurethane-79 and Caprylic / Capric Triglyceride (Oilkemia 5S, Lubrizol), Ethylene / Propylene / Styrene Copolymer and Butylene / Ethylene / Styrene Copolymer and Pentaerythrityl Tetra-di-t-butyl Hydroxyhydrocinnamate and Squalane (Veggi Gel, Aiglon), Dibutyl Lauroyl Glutamide and Dibutyl Ethylhexanoyl Glutamide and Octyldodecanol (AJK-OD246, Ajinomoto).

[0327] The amount of the thickener (e.g. the active thickening polymer), if present is preferably selected in the range of 0.1 to 15 wt.-%, more preferably in the range of 0.5 to 10 wt.-%, most preferably in the range of 1 .0 to 8.0 wt.-%, based on the total weight of the composition.

[0328] The compositions of the invention manage with a surprisingly small total amount of UV filters.

[0329] In another aspect, the composition may have an SPF of at least 15, preferably at least 20, most preferably of at least 30.

[0330] Advantageously in accordance with the invention, the composition of the invention comprises film formers. Film formers in the sense of the present invention are substances of various constitutions, and are characterized by the following properties: When a film former is dissolved in water or other suitable solvents, and when the solution is then applied to the skin, the film former, following evaporation of the solvent, forms a film which serves essentially to fix the UV-filters on the skin and thus to increase the water resistance of the product. It is especially advantageous to select said further film formers from the group of the polymers based on polyvinylpyrrolidone (PVP), as well as Capryloyl Glycerin / Sebacic Acid Copolymer, Diisostearoyl Polyglyceryl-3 Dimer Dilinoleate and / or Ethyl Cellulose, Polyglyceryl-3 Stearate / Sebacate, Stearyl / Octyldodecyl Citrate Crosspolymer, Octyldodecyl Citrate Crosspolymer, Bis-Dodecylhexyldecyl Dimer Dilinoleate / Propanediol Copolymer, Maleated Soybean Oil Glyceryl / Octyldodecanol Esters, polyester-7, polyam ide-8.

[0331] Particular preference is given to copolymers of vinylpyrrolidone, as for example the PVP hexadecane copolymer and the PVP eicosene copolymer, which are available under the trade names Antaron V216 and Antaron V220 from Ashland.

[0332] Likewise advantageous are further polymeric film formers, such as, for example, sodium polystyrene sulfonate, which is available under the trade name Flexan 130 from National Starch and Chemical Corp., and / or polyisobutene, available from Rewo under the trade name Rewopal PIB1000. Examples of further suitable polymers are polyacrylamides (Sepigel 305), polyvinyl alcohols, PVP, PVP / VA copolymers, polyglycols, acrylate / octylacrylamide copolymer (Dermacryl 79). Likewise advantageous is the use of hydrogenated castor oil dimer dilinoleate (CAS 646054- 62-8, INCI Hydrogenated Castor Oil Dimer Dilinoleate), which can be acquired from Kokyu Alcohol Kogyo under the name Risocast DA-H, or else PPG-3 benzyl ether myristate (CAS 403517-45-3), which can be acquired under trade name Crodamol STS from Croda Chemicals.

[0333] The compositions according to the invention in general have a pH in the range of 3 to 10, preferably a pH in the range of 4 to 8 and most preferably a pH in the range of 4 to 7.5. The pH can easily be adjusted as desired with suitable acids such as e.g. citric acid or bases such as NaOH or suitable amines such as tromethamine according to standard methods in the art.

[0334] The amount of the cosmetic composition to be applied to the skin is not critical and can easily be adjusted by a person skilled in the art. Preferably the amount is selected in the range of 0.1 to 3 mg / cm2skin, such as preferably in the range of 0.1 to 2 mg / cm2skin and most preferably in the range of 0.5 to 2 mg / cm2skin. Optional encapsulation

[0335] According to an embodiment, the sunscreen active(s) and / or the cooling compound(s) and / or the cooling enhancing compound(s) and / or the hydrophobic material(s), is at least partly encapsulated, preferably in water soluble starch-based microcapsule or core-shell microcapsules.

[0336] As non-limiting examples, the shell of microcapsules can comprise a material selected from the group consisting of polyurea, polyurethane, polyamide, polyhydroxyalkanoates, polyacrylate, polyesters, polyaminoesters, polyepoxides, organosilicon, polycarbonate, polysulfonamide, urea formaldehyde, melamine formaldehyde resin, melamine formaldehyde resin cross-linked with polyisocyanate or aromatic polyols, melamine urea resin, melamine glyoxal resin, gelatin / gum arabic shell wall, and mixtures thereof.

[0337] Use

[0338] The present invention also relates to the use of the composition according to the invention for protection of skin from the effects skin aging such as wrinkles and as a sun protection composition.

[0339] The present invention also relates to the use of the composition according to the invention for reducing the gloss effect when the composition is applied on the skin.

[0340] The present invention also relates to use of at least one cooling agent for providing a long-lasting cooling effect in a composition comprising at least one sunscreen active agent.

[0341] The present invention further relates to the use of the composition according to the invention as a sun protection composition and for reducing the gloss effect when the composition is applied on the skin. In an embodiment, the use of the composition according to the invention as a sun protection composition and for reducing the gloss effect when the composition is applied on the skin also provides a long-lasting cooling effect. The invention will now be further described by way of examples. It will be appreciated that the invention as claimed is not intended to be limited in any way by these examples.

[0342] EXAMPLES

[0343] Example 1

[0344] Performance of the composition according to the invention (cooling effect)

[0345] All sensorial evaluations have been performed using the emulsion shown in table 1 (R=REFERENCE; l=INVENTION), which were prepared according to standard methods in the art. The determination of the sensorial features was then conducted according to a descriptive sensory evaluation process according to the protocol outlined below:

[0346] - Well-trained panelists evaluated 28 different parameters on a scale from 0-100 compared to references used to calibrate this scale. The parameter cooling was added to the evaluating parameters.

[0347] - Application was done on the forearm volar surface.

[0348] - 50 microliters of the respective emulsion were applied on a spot with an application area of 20 cm2(radius is 2.5cm) corresponding to a topical application of 2.5 mg / cm2

[0349] - After application, the respective emulsion was rubbed in until the product was absorbed by the skin.

[0350] - The parameter “cooling” was evaluated during the rub out.

[0351] - The scoring for the cooling assessment was from 0-10, the value 0 was linked to no cooling up a value of 10 which indicated a significant perceived cooling effect.

[0352] - the individual score values were summed up to give a result on the perceived cooling effect. The higher the value, the higher the perceived cooling effect.

[0353] Table 1 .

[0354] As can be retrieved from the results presented above, an increase of the perceived cooling is observed by the addition of menthol into a composition comprising UV filters. It can also be noted that a significant increase of the perceived cooling was achieved by the addition of a very low dosage of cooling enhancing compound ((E / Z)-2- isopropyl-5-methyl-2-hexenal) to a composition comprising UV filters and a cooling compound.

[0355] Example 2

[0356] Performance of the composition according to the invention (gloss reduced effect)

[0357] All sensorial evaluations have been performed using the emulsion shown in table 2, which were prepared according to standard methods in the art. The determination of the sensorial features was then conducted according to a descriptive sensory evaluation process according to the protocol outlined below:

[0358] - Well-trained panelists evaluated the gloss parameter on a scale from 0-100 compared to references used to calibrate this scale.

[0359] - Application was done on the forearm volar surface.

[0360] - 50 microliters of the respective emulsion were applied on a spot with an application area of 20 cm2(radius is 2.5cm) corresponding to a topical application of 2.5 mg / cm2

[0361] - After application, the respective emulsion was rubbed in until the product was absorbed by the skin. The parameter gloss was evaluated immediate after rub out

[0362] A statistical analysis was done via p value calculation (ANOVA p-value): If the p-value is less than 0.05 a significant difference does exist. Table 2.

[0363] As can be retrieved from the results presented above, a significant reduction of the gloss effect was achieved by the addition of a cooling enhancing compound ((E / Z)-2- isopropyl-5-methyl-2-hexenal) to a composition comprising UV filters and a cooling compound. Example 3

[0364] Performance of a composition according to the invention

[0365] A sensorial evaluation was performed using the emulsion shown in Table 2, except that menthol with or without (E / Z)-2-isopropyl-5-methyl-2-hexenal were used according to Table 3 below. The samples were prepared according to standard methods in the art. The determination of cooling performance and gloss was then conducted according to the descriptive sensory evaluation process described in Examples 1 and 2.

[0366] Table 3.

[0367] The * means there is significant difference vs the cooling agent alone. As shown in Table 3, sample 2 exhibited both a significant increase in cooling performance and a significant decrease in gloss compared to sample 1. Sample 3 showed a significant increase in cooling performance compared to sample 1 .

[0368] Example 4

[0369] Performance of a composition according to the invention

[0370] A sensorial evaluation was performed using the emulsion shown in Table 2, except that the dosages of menthol and (E / Z)-2-isopropyl-5-methyl-2-hexenal were used according to Table 4 below. The samples were prepared according to standard methods in the art. The determination of the cooling performance and gloss was then conducted according to the descriptive sensory evaluation process described in Examples 1 and 2. Table 4.

[0371] Shared letters (“A” or “B”) means that the values were not significantly different. As shown in Table 4, sample 4 exhibited desirable cooling performance and sample 8 exhibited desirable gloss reduction. Samples 5 and 6 exhibited both desirable cooling performance and reduced gloss.

[0372] Example 5

[0373] Performance of a composition according to the invention

[0374] A sensorial evaluation was performed using the emulsion shown in Table 2, except that the cooling agent was menthyl lactate or methyl diisopropyl propionamide (with or without (E / Z)-2-isopropyl-5-methyl-2-hexenal) in the amounts according to Table 5 below. The samples were prepared according to standard methods in the art. The determination of the cooling performance and gloss was then conducted according to the descriptive sensory evaluation process described in Examples 1 and 2.

[0375] Table 5.

[0376] The * means there is significant difference vs the cooling agent alone. As shown in Table 5, sample 10 exhibited a significant increase in cooling performance compared to sample 9. Sample 12 showed both a significant increase in cooling performance and significant decrease in gloss compared to sample 11 .

Claims

CLAIMS1 - A composition comprising:- at least one sunscreen active agent,- at least one cooling compound and / or at least one cooling enhancing compound, and- optionally at least one hydrophobic material.2- The composition according to claim 1 , wherein it comprises at least one cooling compound and at least one cooling enhancing compound.3- The composition according to claim 1 or 2, wherein the at least one sunscreen active agent is an inorganic sunscreen active agent, preferably titanium dioxide or zinc oxide.4- The composition according to claim 1 or 2, wherein the at least one sunscreen active agent is an organic sunscreen active agent, preferably selected from the group consisting of homosalate, ethylhexyl salicylate, polysilicone-15, ethylhexyl methoxycinnamate, octocrylene, phenylbenzimidazole sulphonic acid or a salt thereof, bis-ethylhexyloxyphenol methoxyphenyl triazine, ethylhexyl triazone, diethylhexyl butamido triazone, methylene bisbenzotriazolyl tetramethylbutylphenol, tris-biphenyl triazine, butyl methoxydibenzoylmethane, diethylamino hydroxybenzoyl hexyl benzoate as well as any mixtures thereof.5- The composition according to any one or more of the preceding claims, wherein the total amount of sunscreen active agents in the composition is selected in the range from 1 to 50 wt.-%, preferably from 3 to 40wt.-%, most preferably from 5 to 30 wt.-%, based on the total weight of the composition.6- The composition according to any one or more of the preceding claims, wherein the composition comprises a carrier consisting of at least 30 wt. %, more preferably of at least 40 wt.-%, most preferably of at least 45 wt.-% of water, such as in particular of 50 to 90 wt.-% of water.7- The composition according to any one or more of the preceding claims, wherein the composition is an emulsion, preferably a microemulsion.8- The composition according to claim 7, wherein, the composition is an O / W emulsion comprising an oily phase dispersed in an aqueous phase or an W / O emulsion comprising an aqueous phase dispersed in an oily phase.9- The composition according to anyone of the preceding claims, wherein the cooling compound is chosen in the group consisting of menthol, cubebol, N- ethyl-p-menthyl-3-carboxamide, isopulegol, 3-(L-menthoxy) propane-1 ,2-diol, cis / trans-p-menthane-3,8-diol, 3-(L-menthoxy)-2-methylpropane-1 ,2-diol, 2-[2- (p-menthan-3-yloxy)ethoxy]ethanol, menthoxyethanol, (1 R,2R,4R)-1 -(2- hydroxy-4-methylcyclohexyl)-ethenone, (1 R,2R,5R)-N-ethyl-5-methyl-2-(prop-1 -en-2-yl)-cyclohexanecarboxamide, N-(3-hydroxy-4-methoxyphenyl)-2- isopropyl-5,5-dimethyl-cyclohexanecarboxamide, N-[4-(cyanomethyl)phenyl]-2-isopropyl-5,5-dimethyl-cyclohexanecarboxamide, N-(2-Hydroxy-2- phenylethyl)-2-isopropyl-5,5-dimethyl-cyclohexane-1 -carboxamide, L-menthol lactate, (-)-menthyl ethylene glycol carbonate, (-)-menthone 1 ,2-glycerol ketal, D / L-menthone 1 ,2-glycerol ketal, (-)-menthyl 1 -propylene glycol carbonate, (-)- menthyl 2-propylene glycol carbonate, D / L-menthyl 1 -propylene glycol carbonate, D / L-menthyl 2-propylene glycol carbonate, (1 R,2S,5R)-N-(4- methoxyphenyl)-5-methyl-2-(L-methylethyl)cyclohexanecarboxamide, menthyl ethylamido oxalate, (E)-3-benzo[1 ,3]dioxol-5-yl-N,N-diphenyl-2-propenamide, 3,4-methylenedioxycinnamic acid, N,N-diphenylamide, N,N-dimethyl (-)- menthyl succinimide, (1 R,2S,5R)-N-(4-(carbamoylmethyl)phenyl)- menthylcarboxamide, (-)-menthyl pyrrolidone carboxylate, L-phenylephrine p- menthane carboxamide, (1 R,2S,5R)-N-(4-(cyanomethyl)- phenyl)menthylcarboxamide, (1 R,2S,5R)-N-(2-(pyridin-2- yl)ethyl)menthylcarboxamide, 6-isopropyl-3,9-dimethyl-1 ,4- dioxaspiro[4.5]decan-2-one, (1 R,2R,4S)-dihydroumbellulol, N-ethyl-p- menthane-3-carboxamide, 2-isopropyl-N,2,3-trimethylbutyramide, ethyl 3-(p- menthane-3-carboxamido)acetate, N-ethyl-2,2-diisopropylbutanamide, N-(1 , 1 - dimethyl-2-hydroxyethyl)-2,2-diethylbutanamide, N-cyclopropyl-5-methyl-2-isopropyl-cyclohexanecarboxamide, (-)-menthyl acetoacetate, (-)-menthyl succinate, (-)-menthyl (S)-3-hydroxybutyrate, (-)-menthyl glutarate, 1 -[2- hydroxyphenyl]-4-[2-nitrophenyl]-1 ,2,3,6-tetrahydropyrimidine-2-one, di-(-)- menthyl glutarate, N-(2-hydroxyethyl)-2,3-dimethyl-2-isopropylbutanamide, or any combination thereof.10-The composition according to claim 9, wherein the cooling compound is chosen in the group consisting of N-(1 H-pyrazol-5-yl)-N-(thiophen-2-ylmethyl)-2-(p- tolyloxy)acetamide, menthol, menthyl lactate, N-ethyl-p-menthane-3- carboxamide, 2-isopropyl-N,2,3-trimethylbutyramide, ethyl 3-(p-menthane-3- carboxamido)acetate, N-(Ethoxycarbonylmethyl)-3-p-menthanecarboxamide, isopulegol, cubebol, and mixtures thereof.11 -The composition according to anyone of the preceding claims, wherein the cooling enhancing compound is chosen in the group consisting of(E / Z)-2-isopropyl-5-methyl-2-hexenal, naringenin, methyl acetate, and mixtures thereof.12-The composition according to anyone of the preceding claims, wherein the composition comprises the cooling compound in an amount comprised between 0,01 % and 2%, preferably between 0,1 % and 1 %, more preferably between 0,2% and 0,5% by weight based on the total weight of the composition.13-The composition according to anyone of the preceding claims, wherein the composition comprises the cooling enhancing compound in an amount comprised between 0,001 % and 0,5%, preferably between 0,001 % and 0,2%, even more preferably between 0,005% and 0,1 % by weight based on the total weight of the composition.14- The composition according to anyone of the claims 2 to 13, wherein the ratio between the cooling enhancing compound and the cooling compound is above 1 / 1000, preferably between 1 / 100 and 1 / 10.15-The composition according to anyone of the claims 2 to 13, wherein the composition comprises a mixture of (E / Z)-2-isopropyl-5-methyl-2-hexenal and menthol. 16-The composition according to anyone of the preceding claims, wherein the composition comprises the perfume oil in an amount comprised between 0,01 % and 10%, preferably between 0,05% and 2% by weight based on the total weight of the composition. 17-The composition according to anyone of the preceding claims, wherein the sunscreen active and / or the cooling compound and / or the cooling enhancing compound and / or the hydrophobic material, is at least partly encapsulated, preferably in water soluble starch-based microcapsule or core-shell microcapsules.

Images